human papillomaviru hpv infect hpv-associ penil lesion frequent found male sexual partner women cervic intraepitheli neoplasia cin determin signific find studi preval hpv hpv associ penil lesion male hospit popul non-std complaint penoscopi perform applic acet acid identifi flat lesion papular lesion condylomata acuminata pearli penil papul ppp presenc hpv dna penil scrape test gp5+6+ pcr case hpv posit viral load quantifi us lightcycl base real-time pcr method compar non-std male hospit popul 118 male sexual partner women cin 238 flat penil lesion found penil hpv men respect found presenc penil hpv case hpv posit higher viral load associ presenc flat penil lesion amongst hpv-posit men flat penil lesion common larger size male sexual partner women cin non-std hospit popul hpv infect hpv-associ flat penil lesion commonli found non-std male popul howev lesion frequent present smaller size male sexual partner women cin higher viral load penil scrape male sexual partner women cin reflect higher preval flat penil lesion larger size lesion
kunitz-type proteas inhibitor bikunin known suppress invas metastasi cancer cell hi8 carboxyl-termin domain bikunin activ site glycoprotein increas affin cancer cell construct chimer gene atf-hi8 investig anti-invas anti-migratori activ atf-hi8 ovarian cancer cell atf-hi8-express plasmid atf-express plasmid introduc highli invas metastat ovarian cancer cell line hra properti establish cell line hra/atf-hi8 compar hra/atf hra/luciferas hra/luc control cell line term cell prolifer invas migrat result differ cell prolifer hra/atf-hi8 hra/luc invas migrat hra/atf-hi8 cell significantli inhibit compar hra/luc cell iii migrat invas hra/atf cell significantli inhibit compar hra/luc result indic overexpress atf-hi8 inhibit invas migrat ovarian cancer cell affect cell prolifer suggest hi8 involv anti-invas anti-migratori activ addit atf brought increas anti-migratori activ hi8 find suggest applic therapeut strategi target inhibit periton invas dissemin ovarian cancer us chimer gene atf-hi8
non-infecti human papillomaviru-like particl vlp encod major capsid gene shown effect vaccin prevent cervic cancer develop genet immun gene induc neutral antibodi construct gener recombin adeno-associ viru encod human papillomaviru hpv protein form viru-like particl transduc cell previou report demonstr format vlp necessari induc high titer neutral antibodi protect anim viral challeng carri singl intramuscular i.m inject recombin adeno-associ viru encod hpv-16 protein raav-16l1 balb/c mice ultim produc stronger prolong neutral antibodi compar dna vaccin immunohistochemistri show accumul antigen present cell macrophag dendrit cell raav-16l1 dna-inject muscl fiber due protein express aav infect compar vlp vaccin howev titer neutral antibodi induc vlp higher induc raav-16l1 co-vaccin raav-16l1 adenoviru encod murin gm-csf raav-16l1/rad-mgm-csf induc compar higher level neutral antibodi vlp impli singl i.m co-inject raav-16l1/rad-mgm-csf achiev same vaccin effect vlp vaccin requir booster inject
ovarian carcinoma oc exhibit highli complex cytogenet chang abnorm chromosom segreg mitosi on potenti mechan genom rearrang tumor studi oc demonstr dysfunct short telomer anaphas bridg multipolar mitos supernumerari centrosom normal human ovarian surfac epitheli hose cell transfect human papilloma viru e6/e7 gene subsequ driven telomer crisi same set mitot disturb occur distinct sequenc initi telomer dysfunct follow anaphas bridg supernumerari centrosom multipolar mitos anaphas bridg resolv kinetochor-spindl detach correspond whole-chromosom loss hose karyotyp extens fragment intercentromer dna sequenc correspond high frequenc pericentromer rearrang later passag high degre instabl telomer crisi moder telomeras express centrosom coalesc ultim lead level mitot instabl highli similar cell line complex karyotyp similar observ high-grade oc suggest signific proport structur chromosom chang genom loss caus specif sequenc mitot disturb trigger telomer crisi model produc whole-chromosom gain observ indic chang develop through differ mechan
previous report identif mma1a screen differenti gene express two human melanoma cell line displai divers metastat behavior subcutan inocul nude mice splice variant mma1b identifi through databas homolog search show high degre similar mma1a exon miss exon through extens express profil among normal tumor sampl both mma1a -1b found belong famili cancer-testi antigen studi identifi four addit altern splice mma1 variant name mma1c mma1d mma1e mma1f gener novel mma1 transcript differ mma1a exon exon enlarg becaus us altern splice site intron mma1 gene moreov mma1e lack exon previous mma1b screen express novel mma1 transcript normal tumor tissu demonstr mma1c -1d -1e member cancer-testi antigen famili mma1f found on melanoma metastasi sampl believ express incident furthermor comprehens elucid genom structur mma1 gene characterist featur altern splice mma1 transcript
incid prostat cancer increas markedli past half centuri us data swedish cancer registri follow incid trend ag-specif incid 2002 two differ pattern ag-incid relationship note first on prevail 1995 character preferenti increas incid men older year second pattern increas extend preferenti younger ag group coincid introduct opportunist prostat specif antigen psa screen probabl caus larg upward shift incid 1998 2000 possibl effect diagnost method famili risk estim test compar ag calendar time differ among brother diagnos prostat cancer retriev swedish famili-cancer databas distribut differ accord wilcoxon rank test &lt 0.0001 data suggest diagnosi prostat cancer brother lead earli diagnosi second brother data probabl explain healthi brother seek medic advic diagnosi anoth brother effect like bia famili risk estim
braf gene on human isoform raf activ oncogen ra lead cooper effect cell respond growth factor signal recent somat missens mutat braf gene detect varieti human tumor studi male germ cell tumour gct probabl mutat braf ra oncogen microsatellit instabl msi analys us mono- di-nucleotid marker mutat analysi gct seminoma nonseminoma perform microdissect differ tumour compon express erk1/2 import downstream point converg ra-raf-mek-erk pathwai assess immunohistochem activ braf missens mutat identifi case nonseminoma seminoma mutat 1796t> mutat found embryon carcinoma compon tumor two seminoma nonseminoma exhibit kra gene mutat msi observ tumour seminoma nonseminoma embryon carcinoma microsatellit instabl embryon carcinoma mutat braf gene gct ra mutat intact braf gene identifi constitut activ erk almost tumour test data indic braf gene mutat rare event gct independ kra mutat embryon carcinoma braf mutat link profici tumour repair mismatch base dna find activ erk suggest caus role mapk activ gct independ activ braf ra mutat
aristoloch acid natur occur nephrotoxin carcinogen associ develop urotheli cancer human understand human enzym involv activ detox import assess individu's suscept plant carcinogen us postlabel assai examin abil microsom sampl human liver human kidnei activ aai major compon plant extract metabolit form adduct dna microsom both organ gener dna adduct pattern reproduc found renal tissu human expos deoxyadenosin-n -yl aristolactam deoxyguanosin-n -yl aristolactam deoxyadenosin-n -yl aristolactam identifi aa-dna adduct form aai human hepat renal microsom defin role human microsom enzym activ aai investig modul aai-dna adduct format cofactor select inhibitor microsom reductas cytochrom p450 cyp enzym nadph cyp reductas nadh cytochrom reductas determin whether activ cyp nadph cyp reductas differ human hepat microsom sampl correl level aai-dna adduct form same microsom sampl basi studi attribut most activ aai human hepat microsom cyp1a2 contrast human hepat microsom human renal microsom nadph cyp reductas effect aai activ addit prostaglandin synthas anoth enzym activ aai renal microsom result demonstr first time potenti microsom enzym human liver kidnei activ aai nitroreduct
papillomavirus evolv mechan result escap host immun surveil protein express earli papillomaviru infect deep layer infect epithelium local golgi apparatu endoplasm reticulum protein bovin papillomaviru bpv impair synthesi stabil major histocompat mhc class complex prevent transport cell surfac due retent here show human papillomaviru type hpv-16 caus retent mhc hla class complex imped transport cell surfac rescu treatment interferon unlik bpv hpv-16 doe affect synthesi hla class heavi chain express transport associ antigen process tap result show downregul surfac mhc class molecul common both bpv hpv protein moreov determin hpv-16 downregul surfac express hla-a hla-b present viral peptid mhc class i-restrict cytotox lymphocyt ctl natur killer cell inhibitori ligand hla-c hla-e select downregul cell surfac hla class molecul allow viru establish infect avoid immun clearanc viru-infect cell both ctl cell
prostat-specif antigen psa wide us marker prostat cancer literatur report nonprostat express psa potenti affect earli diagnosi howev result scatter inconclus motiv conduct comprehens studi tissu distribut psa close relat protein human glandular kallikrein hk2 rt-pcr situ hybrid immunohistochemistri us detect express both psa hk2 secretori epitheli cell trachea thyroid gland mammari gland salivari gland jejunum ileum epididymi semin vesicl urethra well leydig cell pancreat exocrin gland epidermi immunometr measur reveal concentr psa nonprostat tissu repres amount normal prostat pronounc express psa detect paneth cell ileum prompt compar function paramet psa ileum prostat found homogen tissu psa manifest equival amidolyt activ capac form complex proteas inhibitor blood vitro psa releas sourc prostat add plasma pool protein given lower level detect site unlik nonprostat psa normal interfer diagnosi prostat cancer nevertheless risk neglect clinic signific under certain circumst supplementari materi articl found intern journal cancer websit http //www.intersci.wilei.com/jpage/0020-7136/suppmat/index.html
hyperthermia import compon cancer treatment protocol studi regul multidrug resist mdr transport p-glycoprotein hyperthermia studi multicellular prostat tumor spheroid hyperthermia treatment small 50-100 microm tumor spheroid significantli increas p-glycoprotein mdr-1 mrna express maximum effect degre wherea moder elev p-glycoprotein found larg 350-450 microm tumor spheroid hyperthermia caus elev intracellular reactiv oxygen speci ro inhibit ro gener nadph-oxidas inhibitor diphenylen iodonium dpi 2-aminoethyl benzenesulfonyl fluorid aebsf abolish p-glycoprotein express affect transcript level heat treatment indic p-glycoprotein level control regul translat rate stabil hyperthermia incub result differenti activ p38 mitogen-activ protein kinas mapk extracellular regul kinas erk1 c-jun n-termin kinas jnk immedi treatment furthermor upregul hypoxia-induc factor 1alpha hif-1alpha observ elev hif-1alpha p-glycoprotein express hyperthermia treatment abolish coadministr p38 inhibitor sb203580 contrast jnk inhibitor sp600125 erk1 inhibitor uo126 result increas hif-1alpha p-glycoprotein control well hyperthermia-treat sampl indic neg regul intrins hif-1alpha p-glycoprotein express erk1 jnk signal cascad summari data demonstr hyperthermia-induc upregul p-glycoprotein hif-1alpha mediat activ p38 wherea erk1 jnk involv repress p-glycoprotein hif-1alpha under control condit
order identifi gene express associ resist chemotherapeut agent oxaliplatin transcript differenti express oxaliplatin sensit stabli resist sublin compar six independ replic us stanford cdna microarrai five cell line signific analysi microarrai sam us identifi gene express statist significantli differ sensit versu resist member cell line pair biochem pathwai kyoto encyclopedia gene genom kegg databas search identifi pathwai number sam-identifi gene exceed number expect identifi four pathwai upregul gene significantli associ resist two cell line pair two pathwai associ found three cell line pair search identifi pathwai downregul gene associ resist two cell line pair on pathwai associ reach statist signific three cell line pair pathwai identifi includ ribosom pathwai huntington's diseas pathwai includ caspas atp synthesi pathwai determin chromosom locat sam-identifi gene reveal sever local gene lai close proxim includ three gene apacd if-2 rev1l locat chromosom lie immedi adjac significantli upregul three five cell line pair biochem pathwai chromosom map gene identifi sam differenti express relat cell line pair point mechan chromosom site previous suspect associ oxaliplatin-resist phenotyp
chemoprevent ag effect cancer control modal howev search novel agent armamentarium cancer chemoprevent continu argu agent capabl interven on critic pathwai carcinogenesi process will greater advantag singl-target agent pomegran fruit extract pfe deriv tree punica granatum possess strong antioxid antiinflammatori properti pomegran fruit extract aceton analyz base matrix-assist laser desorpt/ioniz time-of-flight mass spectrometri found contain anthocyanin ellagitannin hydrolyz tannin evalu whether pfe possess antitumor-promot effect first determin effect topic applic pfe cd-1 mice 12-o-tetradecanoylphorbol-13-acet tpa -induc convent marker novel marker skin tumor promot found topic applic pfe mg/mous min prior tpa 3.2 nmole/mous applic mous skin afford signific inhibit time-depend manner tpa-mediat increas skin edema hyperplasia epiderm ornithin decarboxylas odc activ protein express odc cyclooxygenas-2 found topic applic pfe result inhibit tpa-induc phosphoryl erk1/2 p38 jnk1/2 well activ nf-kappab ikkalpha phosphoryl degrad ikappabalpha assess effect skin applic pfe tpa-induc skin tumor promot 12-dimethylbenz anthracen-initi cd-1 mous anim pretreat pfe show substanti reduc tumor incid lower tumor bodi burden assess total number tumor per group percent mice tumor number tumor per anim compar anim receiv pfe tpa-treat group 100 mice develop tumor week test wherea time pfe-treat group mice exhibit tumor skin applic pfe prior tpa applic result signific delai latenc period week afford protect tumor data consid term tumor incid tumor multipl result studi provid clear evid pfe possess antiskin-tumor-promot effect cd-1 mous becaus pfe capabl inhibit convent well novel biomark tpa-induc tumor promot possess chemoprevent activ wide rang tumor model in-depth studi defin activ agent pfe capabl afford antitumor-promot effect warrant
previous demonstr jte-522 select cyclooxygenas-2 cox-2 inhibitor inhibit develop aberr crypt foci acf rat put preneoplast lesion colon suggest inhibitori potenti rat colon carcinogenesi evalu chemoprevent properti jte-522 present studi design evalu inhibitori effect jte-522 rat colon tumorigenesi induc 2-dimethylhydrazin dmh rat week ag divid group on week start experi rat receiv dmh s.c inject dose mg/kg bodi weight onc week success week initi postiniti treatment group group 1-3 fed diet contain 150 ppm jte-522 respect start studi postiniti treatment group group given 150 ppm jte-522 week dmh inject studi forti week start experi administr 150 ppm jte-522 both initi postiniti stage significantli inhibit incid tubular adenocarcinoma total carcinoma well total tumor colon inhibitori effect jte-522 most promin tubular adenocarcinoma observ nontubular carcinoma signet-ring cell mucin carcinoma almost equal inhibitori effect tubular adenocarcinoma observ rat given 150 ppm jte-522 postiniti stage suggest major anticanc action postiniti phase howev jte-522 effect size invas extent tubular adenocarcinoma furthermor microarrai analys reveal jte-522 effect gene express level dmh-induc tubular adenocarcinoma find suggest jte-522 possess chemoprevent activ induct progress tubular adenocarcinoma rat colon view signific inhibitori effect jte-522 acf major anticanc action occur postiniti stage befor malign convers stage dmh-induc colon carcinogenesi
genet factor us assess risk prostat cancer develop evalu prostat cancer outcom includ clinic prognosi treatment method treatment respons assess role famili histori prostat cancer outcom evalu tumor characterist diagnost precursor biochem prostat specif antigen relaps-free surviv men famili histori prostat cancer total 684 prostat cancer case unselect famili histori identifi ongo hospit base prostat cancer case-control studi 1995 2002 self-report famili histori group categori none moder on affect first second degre rel high affect first second degre rel consid group defin earli befor ag late ag ag diagnosi overal tumor stage significantli associ odd ratio [or] 1.43 confid interv [ci] 1.00-2.05 moder 1.48 1.0-2.19 famili histori men diagnos befor ag howev higher tumor stage 2.19 1.28-3.75 moder 2.15 1.2-3.9 famili histori men diagnos ag famili histori significantli like experi biochem psa failur hazard ratio [hr] 2.60 1.08-6.25 men moder famili histori significantli increas risk biochem failur 2.49 1.25-4.95 2.46 1.17-5.16 respect moder famili histori increas probabl semin vesicl invas 2.14 1.06-4.34 result suggest famili histori prostat cancer associ predictor clinic outcom prostat cancer case unselect famili histori prostat cancer
proteas activ receptor par form famili g-protein coupl receptor gpcr encod own ligand uniqu activ via proteolyt cleavag proteas gener implic remodel extracellular tumor microenviron role cell surfac receptor activ proteolysi emerg present studi investig express pattern proteas activ receptor hpar1 ovarian carcinoma tissu sampl abund hpar1 mrna protein detect low malign potenti invas carcinoma regardless histolog subtyp contrast hpar1 express detect cell surfac normal ovarian epithelium differenti express pattern hpar1 shown situ hybrid immunohistochemistri semi-quantit rt-pcr analys earli stage ovarian carcinoma contra later normal ovari show strong par1 express oppos lack express ovarian epithelium obtain normal individu parallel analyz express pattern alphavbeta5 integrin activ focal adhes kinas fak major focal contact protein tissu abund express alphavbeta5 integrin observ tissu specimen examin regardless normal malign level activ fak differenti express phosphoryl fak invas ovarian carcinoma normal ovarian epithelium abund hpar1 level patholog malign ovarian carcinoma like transmit signal lead phosphoryl fak therebi alter integrin function state altogeth data suggest hpar1 fak cooper promot ovarian cancer malign
conduct hospit-base case-control studi algier algeria total 198 cervic carcinoma case includ adeno- adenosquam carcinoma 202 ag-match control women includ human papillomaviru hpv dna cervic cell evalu us pcr assai odd ratio correspond confid interv comput mean uncondit multipl logist regress model hpv infect detect 97.7 case 12.4 control women 635 nineteen differ hpv type found hpv most common type both case control women follow hpv twelv type hpv found singl infect case multipl hpv infect show higher odd ratio singl infect addit hpv infect husband's extramarit sexual relationship women 4.8 prostitut 3.2 resid rural environ most on's life 4.9 indic poor sanit poor hygien strongest risk factor oral contracept us unrel risk multipar emerg signific risk factor adjust sexual habit intrauterin devic user show lower risk nonus role major risk factor except insid toilet confirm analysi restrict hpv-posit women distribut hpv type case control women algeria similar on found europ on sub-saharan africa hpv preval vaccin hpv effect 3/4 cc algeria
beta-catenin role nuclear signal molecul implic prostat carcinogenesi primarili through modul androgen receptor activ defin pattern beta-catenin protein express nuclei normal hyperplast malign human prostat tissu determin whether differ express associ diseas progress prognosi five normal prostat benign prostat hypertrophi specimen 232 radic prostatectomi specimen patient clinic local prostat cancer case advanc assess beta-catenin express us immunohistochemistri nuclear beta-catenin express local significantli lower benign prostat tissu &lt 0.001 significantli higher advanc tissu &lt 0.001 addit lower level nuclear beta-catenin express &lt cancer cell predict shorter biochem relaps-free surviv patient local 0.008 invers correl preoper prostat-specif antigen psa level 0.01 analysi low-risk subgroup patient preoper psa level &lt ng/ml demonstr lower level nuclear beta-catenin express &lt cancer cell predict poorer prognosi 0.006 conclus lower level nuclear beta-catenin express found malign compar benign prostat tissu addit lower nuclear beta-catenin express associ poorer prognosi local particular low-risk subgroup patient preoper psa level &lt ng/ml level nuclear beta-catenin express clinic util preoper prognost marker low-risk local
purpos optim manag patient advanc ovarian primari periton cancer receiv achiev excel respons neoadjuv chemotherapi remain undefin method five patient briefli present found extens intra-abdomin carcinomatosi ovarian/periton cancer initi treat carboplatin/paclitaxel-base neoadjuv chemotherapi program major object subject respons patient underw surgic re-assess subsequ receiv singl-agent intraperiton platinum cisplatin carboplatin result conclus absenc definit data random phase-3 trial defin optim manag set ration argument provid support us multi-modal manag strategi neoadjuv chemotherapi follow surgeri region chemotherapi carefulli select patient present extens ovarian primari periton cancer
purpos glioblastoma multiform gbm repres prototyp angiogen tumor recent continu low-dose schedul chemotherapeut drug combin inhibit cyclooxygenas-2 cox-2 suggest novel anti-angiogen approach aim studi evalu safeti activ continu low-dose temozolomid tmz plu cox-2 inhibitor rofecoxib patient newli diagnos gbm method vitro endotheli cell character tenfold higher sensit tmz glioma cell consequ subgroup patient incomplet resect gbm divid three group aim dose escal 1/10 daili mtd tmz tmz mg/m2 everi third dai rofecoxib mg/d tmz mg/m2/d rofecoxib mg/d tmz mg/m2 twice dai rofecoxib 12.5 twice dai cox-2 vegf vegf receptor-2 cd34 assess immunohistochem clinic set result mean follow-up period month observ sever toxic attribut therapi qualiti life impair whole studi popul median time progress overal surviv month month respect immunohistochemistri suggest tumor higher vessel densiti character significantli better control lower vessel densiti conclus continu low-dose tmz plu rofecoxib feasibl safe maintain good qualiti life studi indic anti-angiogen efficaci continu low-dose tmz plu rofecoxib gbm especi tumor character high angiogen activ
integr literatur review focus spectrum cardiovascular late effect factor influenc develop cardiovascular late effect role pediatr oncolog nurs minim risk cardiovascular late effect associ disabl childhood cancer survivorship result show survivor treat radiat therapi especi field includ heart hypothalam-pituitari axi hpa specif chemotherapi increas risk develop particular cardiovascular risk factor cardiovascular diseas younger ag diagnosi longer time treatment famili histori earli heart diseas heighten risk role pediatr oncolog nurs promot cardiovascular health children cancer across ill trajectori discuss
4-thiadiazolidin deriv shown involv sever biolog respons anti-bacteri anti-fungal anti-tubercular local anaesthet activ studi synthes 5-substitutedarylimino-2-n-substitutedphenyl-3-oxo-1 4-thiadiazolidin test anti-inflammatori anti-tumor activ 4-methoxyarylimino -2-n- 4-dichlorophenyl -3-oxo-1 4-thiadiazolidin -25 show anti-inflammatori activ inhibit differ inflammatori induc mediat nuclear transcript factor kappa nf-kappab kei transcript factor involv form inflamm -25 inhibit tnf-induc nf-kappab activ detect gel shift assai depend report gene express inhibit ikappabalpha degrad ikappab kinas activ p65 nuclear transloc -25 inhibit tnf-induc cox2 express inhibit nf-kappab activ human epitheli cell unlik substitutari deriv -25 potent induc apoptosi induc cell death caspas-depend parp cleavag roi gener lipid peroxid overal result suggest -25 deriv exert anti-inflammatori anti-tumor activ role design drug
overexpress cyclooxygenas cox implic patholog condit includ cancer on practic infer find sustain inhibit cox-2 serv promis target prevent therapi cancer convent nonsteroid antiinflammatori drug nsaid recent develop cox-2-specif inhibitor shown consider promis prevent form human cancer howev applic limit due sever toxic side effect normal cell need defin novel nontox dietari constitu proven chemoprevent effect through pathwai possess cox-2 cox-1 inhibitori activ recent studi green tea major polyphenol constitu epigallocatechin-3-gallat egcg establish remark cancer prevent cancer therapeut effect here show egcg inhibit cox-2 affect cox-1 express both mrna protein level androgen-sensit lncap androgen-insensit pc-3 human prostat carcinoma cell base studi tempt suggest combin egcg chemotherapeut drug improv strategi prevent treatment prostat cancer
advanc prostat cancer cellular chang occur lead transit androgen-depend androgen-independ growth transit prolifer androgen-depend prostat cancer cell becom depend growth factor like epiderm growth factor egf endocytosi growth factor receptor on mechan control growth factor signal observ markedli chang advanc metastat prostat cancer internalis signal egf receptor examin differ prostat cancer cell line relat express level endocytosi-relat rep2 gene observ high level rep2 correl reduc egf-internalis investig thoroughli prostat cancer cell induc rep2 express gener us cell found rep2-induct inde result reduct egf-internalis furthermor egf receptor signal evalu examin mrna express sever egf-respons gene egf receptor egr-1 fo jun observ induc express rep2 exert inhibit effect signal experi conclud increas rep2 express neg affect egf receptor internalis subsequ signal decreas rep2 express prostat cancer progress observ earlier work result enhanc egf receptor express signal add androgen-independ state advanc prostat cancer
androgen withdraw effect therapi patient advanc prostat cancer progress androgen independ ultim occur almost patient novel therapeut strategi target molecular mechan mediat resist hormon chemotherapeut treatment highli warrant here aim evalu express potenti therapeut target advanc prostat cancer tissu microarrai tma contain sampl 535 tissu block construct includ benign prostat hyperplasia control prostat intraepitheli neoplasia pin clinic local prostat cancer 181 well hormon-refractori local recurr 120 distant metastas express differ protein analyz us immunohistochemistri bcl-2 p53 ilk syndecan-1 muc-1 egfr her2/neu hsp-90 ep-cam mmp-2 cd-10 cd-117 ki67 signific overexpress hormon-refractori prostat cancer metastat tissu compar local prostat cancer found ki67 bcl-2 p53 syndecan-1 egfr her2/neu overexpress cd-117 restrict singl metastasi marker show relev differ express subgroup taken togeth p53 bcl-2 syndecan-1 egfr her2/neu preferenti express hormon-refractori metastat prostat cancer select inhibit target offer strategi treat advanc tumor prevent progress treatment decis base find primari tumor rather tissu recurr metastat lesion
liver cancer poor prognosi lack effect therapi previous demonstr intraport inject adeno-associ-viral aav particl express angiostatin lead long-term express angiostatin capabl suppress outgrowth el-4 tumor liver here combin aav-mediat angiostatin therapi immunotherapi emploi aav vector encod t-cell costimul b7.1 incub el-4 cell aav-b7.1 virus result rapid express b7.1 surfac el-4 cell mice vaccin b7.1-engin tumor cell reject tumor cell resist secondari challeng unmodifi parent cell splenocyt vaccin mice highli cytotox parent el-4 cell vitro howev vaccin mice fail resist challeng heavi burden el-4 cell intraport inject aav particl express angiostatin mice vaccin month earlier b7.1-engin tumor cell protect mice challeng heavi burden el-4 cell erad tumor dissemin liver combin therapi increas surviv rate mice advanc liver cancer encourag result warrant investig employ anti-angiogen therapi subsequ cancer immunotherapi target unresect dissemin liver metastas
high-level express cyclooxygenas cox report 80-90 colorect adenocarcinoma select inhibit cox-2 shown reduc colorect tumorigenesi differ model carcinogenesi prevent metastasi xenograft tumor model well suppress vitro induc angiogenesi recent cox-2 report express malign epitheli cell neovasculatur feed tumor varieti solid human cancer on possibl mechan select cox-2 inhibitor reduc tumor growth metastasi through inhibit tumor angiogenesi report suggest possibl role endotheli cox-1 process angiogenesi recent studi select inhibit cox-2 shown strongli inhibit angiogenesi induc endotheli cell apoptosi present studi us human umbil vein endotheli cell huvec model angiogenesi investig potenti antiangiogen effect select cox-2 inhibitor mechan action clearli demonstr select inhibit cox-2 caus dose-depend decreas prolif activ ec well inhibit capillari-like tube format inhibitori effect prolifer depend cell cycl arrest phase cell apoptosi
trial perform determin efficaci progress-free overal surviv patient advanc ovarian cancer treat intraperiton hypertherm chemotherapi iphc ten patient advanc ovarian cancer particip trial treat iphc median progress-free overal surviv rate patient treat studi 41.2 70.2 month respect two ten patient receiv optim primari cytoreduct surgeri follow iphc four ten optim interv debulk surgeri follow iphc four ten neg second-look oper follow iphc group 14.5 17.75 82.75 130.25 month median progress-free overal surviv rate respect grade 3-4 toxic includ myelosuppres nephropathi detect on patient requir blood transfus due grade anemia thrombocytopenia anoth patient develop grade nephrotox requir continu hemodialysi iphc feasibl produc manag toxic show promis treatment advanc ovarian cancer neg second-look laparotomi follow iphc especi effect consolid intraperiton chemotherapi indic produc excel median progress-free overal surviv rate
investig ny-eso-1 lage-1a mrna express normal tissu variou type cancer quantit real-time rt-pcr addit high express testi observ low express ny-eso-1 mrna placenta pancrea liver express normal tissu observ low express lage-1a mrna placenta ovari margin express normal tissu contrast previou find ny-eso-1 lage-1a mrna mostli co-express solid tumor found independ express ny-eso-1 lage-1a mrna ny-eso-1 mrna express mostli associ lage-1a mrna express esophag liver cancer prostat cancer immunohistochemistri ihc us ny-eso-1-specif es121 mab show ny-eso-1 protein detect ny-eso-1 mrna-posit specimen esophag liver cancer respect ny-eso-1 protein express correl copi number ny-eso-1 mrna ihc perform us es121 mab b9.8 mab recogn both ny-eso-1 lage-1a esophag liver cancer specimen preferenti express lage-1a mrna b9.8-specif stain observ weakli focal on liver cancer specimen express copi lage-1a mrna
tnf-like weak induc apoptosi tweak induc divers cellular respons includ cell death inflamm migrat prolifer variou transform cell line investig tweak sensit tweak effect nuclear factor-kappab activ express tweak ht-29 ls180 sk-co-1 sw480 human colon adenocarcinoma cell line express tweak receptor fn14 tweak alon induc cell death sw480 cell induc cell death ht-29 cell addit ifn-gamma actinomycin cycloheximid tweak affect cell viabil ls-180 sk-co-1 cell activ nf-kappab obvious influenc tweak cell line four human colon adenocarcinoma cell line constitut express tweak mrna protein membran-bound tweak antigen detect rt-pcr western blot flow cytometri stimul anticanc drug camptothecin augment cell surfac express tweak human colon adenocarcinoma tissu sampl studi demonstr posit stain tweak antigen solubl tweak detect cultur medium cell line elisa condit medium sw480 cell incub anti-tweak antibodi significantli inhibit endotheli cell tube format matrigel function express tweak human colon adenocarcinoma cell contribut neovascular
recombin adeno-associ viru type raav properti ideal vector gene therapi broad spectrum suscept cell effici gene transfer persist transgen express vivo indict vector-relat toxic ovarian carcinoma cell line howev previous report resist raav transduct us optim adenoviru-free packag system highli purifi raav vector code enhanc green fluoresc protein aav/egfp mcd40 ligand aav/cd40l gener transduct effici ovarian carcinoma cell line assess irradi prior infect measur flow cytometri transgen express cell achiev aav/egfp gamma-irradi significantli increas transduct rate 3.5-fold cell line low suscept aav infect aquir capabl aav/cd40l transduc tumor cell activ dendrit cell demonstr second step dendrit cell gener human peripher blood monocyt matur stimul il-4 gm-csf co-cultiv mcd40l transgen tumor cell dendrit cell result strong elisa-determin express il-12 indic dendrit cell activ conclud transduct tumor cell raav encod mcd40l promis strategi tumor immunotherapi develop vaccin approach transgen ovarian carcinoma cell gener vivo transduct
clear cell carcinoma ovari consid specif subtyp among epitheli ovarian malign character clear cell carcinoma earli figo stage i-ii regard clinic biolog properti retrospect studi perform compar tumor histolog subtyp complet seri 226 patient epitheli ovarian carcinoma figo stage i-ii patient clear cell carcinoma select clinic biolog characterist tumor compar remain non-clear cell carcinoma patient underw primari stage laparotomi follow adjuv radiotherapi chemotherapi apoptosi regul p53 bcl-2 bax growth factor receptor egfr her-2/neu analyz immunohistochem techniqu dna analysi perform flow cytometri clear cell carcinoma stain neg p53 significantli histolog subtyp posit egfr stain frequent serou carcinoma clear cell carcinoma aneuploid dna statu frequent clear cell carcinoma histolog subtyp tetraploid tumor made non-diploid tumor clear cell tumor frequent found figo stage iic common non-clear cell tumor differ found rate tumor recurr surviv patient clear cell non-clear cell carcinoma clear cell carcinoma ovari regard separ entiti among epitheli ovarian carcinoma differ regard both clinic biolog characterist compar non-clear cell tumor
hypoxia-induc factor-1 hif-1 on kei mammalian transcript factor show increas level both protein stabil intrins transcript activ low oxygen tension hypoxia-activ function hif-1 protein bind hypoxia-respons element hre enhanc sever gene includ vegf major player angiogenesi initi mrna express molecular mechan regul gene express under hypox condit increas therapeut window tumor-specif deliveri system studi examin hypoxia-specif product anti-angiogen therapeut gene construct copi hre 5xhre human vegf link solubl tie2 stie2 driven minim sv40 promot 5xhre/sv40/stie2 data show under hypoxia secret stie2 select inhibit tube format migrat capac endotheli cell vitro henc propos vector system 5xhre/sv40/stie2 us tool down-regul tumor angiogenesi under hypox condit
insulin-like growth factor-i igf-i plai import role prostat growth hyperplasia carcinogenesi circul igf-i level modul genet cytosin-adenin repeat polymorph promot region igf-i associ polymorph risk prostat cancer benign prostat hyperplasia bph explor 303 patient prostat cancer 219 patient bph 262 control number repeat rang case control subject 19-ca-repeat allel 19-allel frequent observ both prostat cancer bph patient compar control prostat cancer versu control p&lt 0.001 bph versu control 0.001 compar non-carrier 19-allel men homo-zygou 19-allel significantli increas risk prostat cancer [ag-adjust odd ratio aor 3.36 confid interv 1.30-8.67 0.012] bph aor 3.53 1.32-9.46 0.012 heterozyg 19-allel intermedi increas risk prostat cancer aor 1.78 1.25-2.53 0.001 bph aor 1.66 1.14-2.43 0.009 gene dosag effect aor found increas number 19-allel p&lt 0.001 prostat cancer 0.001 bph signific associ found presenc 19-allel tumor stage grade time diagnosi conclus 19-allel igf-i appear increas risk prostat cancer bph gene dosag effect japanes popul
investig vitro effect baicalein baicalin human umbil vein endotheli cell huvec human prostat tumor cell du-145 pc3 well effect oral administ baicalein growth du-145 cell subcutan inject scid mice vitro effect baicalein baicalin treatment human prostat cancer cell line du-145 pc-3 assess emploi cell prolifer mt assai cytotox live/dead assai tunel assai vitro anti-prolif anti-angiogen properti baicalein baicalin studi huvec sprout assai effect oral administ baicalein tumor growth scid mice studi four group anim inject subcutan du-145 cell treat daili dai control group receiv vehicl carboxymethylcellulos wherea three group receiv escal dose baicalein mg/kg per dai baicalein baicalin exhibit dose-depend growth inhibitori effect human prostat cancer cell umbil vein endotheli cell vitro treatment two flavonoid compound significantli decreas averag number length sprout form endotheli cell aggreg dose-depend manner vivo treatment mice baicalein demonstr statist signific tumor volum reduct p&lt 0.01 compar control first studi demonstr vivo growth inhibitori effect oral administ baicalein human prostat tumor mice
high grade prostat intraepitheli neoplasia pin atyp adenomat hyperplasia aah discuss precursor prostat cancer unlik high grade pin relat aah howev unclear present studi analyz aah accompani prostat carcinoma carcinoma transit zone microdissect us compar genom hybrid cgh multipelx-pcr microsatellit polymorph marker everi case non-neoplast prostat tissu investig same allel imbal two aah show allel imbal multiplex-pcr imbal correl correspond tumour furthermor differ loh found investig prostat tumour transit zone on aah show loss chromosom 22q found allel imbal non-neoplast tissu adjac prostat carcinoma find support idea aah doe seem link close consid oblig premalign lesion
normal human diploid cell limit life span undergo replic senesc variou limit popul doubl cell pass senesc barrier becom immort exact mechan immort clear inactiv pathwai p53 pathwai activ telomeras shown necessari immort certain cell type dna virus htert methyl-associ inactiv tumor suppressor gene plai import role tumor progress test gene-specif methyl contribut immort transform phenotyp analyz methyl statu gene normal cell immort sv40 htert ad5 ad12-sv40 hpv-18 immort line progress transform tumorigen nude mice observ gene-specif methyl vitro immort transform cell sv40 hpv18 immort result differ methyl spectra sv40- h-tert-immort prostat epitheli cell most frequent methyl gene rassf1a hpv18-immort cell line rar-beta2 gene univers methyl immort sv40 result methyl greater number gene immort hpv furthermor sv40-immort cell line methyl affect differ gene fibroblast compar epitheli cell suggest differ mechan us sv40 immort cell line differ origin hpv18-immort subsequ transform cell line most commonli methyl gene hormon respons gene er-beta rar-beta2 gener gene methyl neoplast-transform cell line immort cell line indic accumul epigenet abnorm contribut oncogenesi
multidrug resist mdr remain major obstacl treatment human cancer recent discov breast cancer resist protein bcrp/abcg2 found import mediat chemotherapeut mdr fumitremorgin ftc select potent inhibitor bcrp complet inhibit revers bcrp-mediat resist micromolar concentr report studi pharmacokinet tissu distribut ftc administ intraven dose mg/kg femal scid mice bear bcrp-overexpress human ovarian xenograft igrov1/t8 tumor plasma pharmacokinet tissu distribut ftc variou organ tissu studi addit effect ftc administr express bcrp tumor assess rt-pcr administr singl ftc dose appear caus major toxic result pharmacokinet data fit two-compart model us nonmem ftc clearanc determin 0.55 ml/min 25.0 ml/min/kg inter-anim variabl area under plasma concentr time curv determin bailer's method calcul 1128+/-111 microg min/ml ftc wide distribut tissu assai highest concentr found lung liver kidnei decreas order respect ftc appear effect express bcrp tumor administ dose recov urin fece suggest hepat metabol primari mechan elimin current studi us basi futur anim vivo studi ftc design understand impact bcrp drug resist
studi design determin cytolog detect 5-methylcytosin 5mc feasibl prostat tumor section determin level 5mc differ malign compar normal prostat tissu sought 5mc level correl clinic outcom data thirti prostat tumor section obtain patient underw radic prostatectomi 1988 1995 repres mix low high grade tumor clinic data maintain patient minimum year follow section stain commerci avail antibodi 5mc immunocytochemistri level subsequ quantifi us comput-assist true-color imag system tumor benign region same archiv section compar addit seri normal prostat sampl prostat cancer cell exhibit pronounc global decreas methyl compar benign normal tissu observ patient 96.7 studi densitometr scan methyl stain indic valu quantifi overal higher methyl valu detect men posit surgic margin recurr diseas data suggest loss methyl featur prostat cancer partial gain methyl presum promot specif gene associ clinic outcom measur us whole-cell assai
unclassifi sex cord-stromal tumor account small proport pediatr testicular tumor most clinic benign demonstr malign potenti histolog find correl well clinic behavior cytogenet aid both diagnosi predict clinic behavior data sex cord-stromal tumor scarc describ unclassifi sex cord-stromal tumor occur testi prepubert male evid metastasi previous unreport +12 +13 +18 +19 +20 karyotyp
cytogenet analysi case metastat granulosa cell tumor recur year oophorectomi reveal monosomi anomali typic granulosa cell tumor coupl patholog immunophenotyp find assist establish proper diagnosi lesion absenc origin histopatholog slide
vaccin-induc cd8 cell direct tumour-specif antigen recognis import compon protect therapeut immun tumour tumour antigen pathogen potenti immunogen epitop lost tumour develop subunit vaccin consist multipl individu epitop attract altern immunis whole tumour antigen present studi investig efficaci two dna-base multiepitop 'polytop' vaccin contain murin h-2b human hla-a*0201 -restrict epitop oncoprotein human papillomaviru type elicit tumour-protect cytotox t-lymphocyt ctl respons show first polytop elicit power effector ctl respons measur ifn-gamma elispot long-live memori ctl respons measur function ctl assai tetram immunis mice respons boost immunis recombin vaccinia viru express polytop respons induc immunis polytop dna alon partial protect infect recombin vaccinia viru express polytop complet protect afford challeng e7-express tumour reduc growth nascent tumour observ second polytop differ exact composit order ctl epitop lack insert endoplasm reticulum target sequenc t-helper epitop induc much poorer ctl respons fail protect tumour challeng observ indic valid dna polytop vaccin approach human papillomaviru e7-associ carcinoma underscor import design polytop vaccin construct
cyclooxygenas-2 cox-2 express mediat constitut nuclear factor -kappab aim studi investig associ germlin alter nf-kappab bind site cox-2 risk develop variou type human cancer us pcr dna sequenc analysi perform hospit-base case-control studi involv variou type human cancer name cervic breast lung bladder cancer cox-2 gene sequenc 217 korean individu 122 cancer patient non-cancer patient identifi novel polymorph -1166 c--> -1186 t--> nf-kappab bind promot region cox-2 polymorph nucleotid 1186 found associ increas risk bladder cancer 0.038 howev case cancer signific associ found polymorph cox-2 promot region risk cancer conclus result suggest polymorph nucleotid -1186 nf-kappab bind promot region cox-2 gene associ increas risk bladder cancer research need investig function implic polymorph cox-2 promot gene human cancer
object studi show exclud effect dietari supplement rise prostat-specif antigen psa level studi effect dietari supplement verum administ week contain plant estrogen antioxid includ carotenoid selenium put prostat cancer inhibit substanc random placebo-control doubl-blind crossov studi hormon untreat men prostat cancer increas psa level outcom measur chang rate chang serum concentr total free psa chang male sex hormon level male sex hormon level significantli lower verum phase dht -0.11 nmol/l 0.005 testosteron nmol/l 0.02 total psa doubl time unaffect free psa increas placebo phase averag doubl time week decreas verum period averag half-life week 0.02 men free androgen index decreas signific decreas slope both total free psa observ 0.04 overal total psa doubl time increas significantli verum howev studi demonstr dietari intervent reduc dht testosteron level increas free psa doubl time total psa doubl time relev subgroup futur studi confirm observ translat slow diseas progress dietari intervent becom attract option prostat cancer treatment prevent
celecoxib potent nonsteroid antiinflammatori drug nsaid shown great promis cancer chemoprevent treatment tumor suppress activ celecoxib nsaid relat induct apoptosi cancer cell line anim model celecoxib specif inhibitor cyclooxygenas cox recent data indic apoptot properti mediat through cox-independ pathwai studi evalu second gener celecoxib deriv lack cox-2 inhibitori activ premalign malign human oral cell cultur model determin potenti anticanc effect mechan respons cox-independ apoptot activ celecoxib deriv delai progress cell through phase induc apoptosi deriv apolar substitu termin phenyl moieti celecoxib greatli enhanc apoptosi cell cycl delai apoptosi cell cycl arrest appear independ deriv induc inhibit pdk1 phosphoryl akt erk1/2 deriv induc apoptosi mediat cleavag activ caspas-9 caspas-3 caspas implic mitochondri pathwai apoptosi induct inhibitor caspas-3 caspas-9 cyclosporin mitochondri membran potenti stabil attenu deriv induc apoptosi inhibit caspas-3 prevent activ caspas inhibit caspas-9 inhibitor block activ both caspas deriv apoptosi independ bcl-2 result indic second gener celecoxib deriv induc apoptosi human oral cancer line disrupt mitochondri membran potenti activ caspas downstream caspas suggest modif celecoxib structur lead highli effect cox-independ growth inhibitori apoptot agent chemoprevent therapi
g-protein-coupl receptor signal transduct pathwai repres import specif target varieti human diseas rang control blood pressur allerg respons hormon disord neurolog diseas tumorigenesi most recent other identifi novel human prostat-specif g-protein coupl receptor psgr investig potenti role psgr human normal prostat prostat cancer examin express level psgr 146 human prostat sampl real-time quantit revers transcript-pcr situ hybrid method significantli extend previou studi demonstr psgr specif express human prostat tissu normal tumor sampl test compar normal benign prostat hyperplasia tissu express psgr increas significantli human prostat intraepitheli neoplasia pin prostat tumor approxim 10-fold especi earli prostat tumor suggest psgr plai import role earli prostat cancer develop progress sensit specif estim psgr express calcul area under receiv-oper characterist curv 0.902 indic high-level sensit specif discrimin benign prostat tissu malign prostat tissu associ psgr express clinic paramet clinic stage gleason score recurr statu metastasi investig studi data suggest overexpress psgr human pin prostat cancer potenti earli prostat cancer detect diagnosi
centrosom abnorm found variou cancer type thought involv earli develop cancer progress contribut centrosom abnorm ovarian tumorigenesi previous evalu sought determin whether centrosom dysfunct occur ovarian tumorigenesi whether us indic earli neoplast chang ovarian surfac epithelium os primari cultur normal os ovarian tumor well paraffin-embed normal ovari ovarian tumor differ stage us immunostain gamma-tubulin antibodi centrosom consid abnorm per cell size greater 2-fold normal centrosom abnorm shape centrosom normal tissu uniform size wherea centrosom ovarian tumor tend abnorm size number shape averag 4.7 cell primari normal os cultur centrosom wherea 14.1 primari cell ovarian tumor displai centrosom abnorm 0.008 centrosom abnorm present 60.9 stage 83.3 stage stage iii paraffin-embed ovarian tumor sampl examin normal tissu addit centrosom abnorm occur frequent ovarian tumor higher grade aggress serou subtyp first demonstr centrosom abnorm occur ovarian tumor centrosom dysfunct earli event ovarian carcinogenesi involv ovarian tumor progress
beyond human papillomaviru hpv infect host genet factor contribut cervic carcinogenesi studi aim test hypothesi ca-dinucleotid repeat polymorph first intron interferon-gamma ifn-gamma gene associ hpv-initi cervic carcinogenesi hospit-base case-control studi includ patient low-grade squamou intraepitheli lesion lsil high-grade squamou intraepitheli lesion hsil 123 invas carcinoma 153 uterin cervix well ag-match control conduct ifn-gamma genotyp determin pcr capillari electrophoresi intern standard hpv genotyp determin consensu pcr revers line blot hybrid genotyp contain allel repeat significantli common patient hsil control 3.0 1.7-5.2 &lt 0.0001 contrast genotyp contain significantli common control patient hsil 0.3 0.2-0.6 0.0001 squamou cell carcinoma 0.6 0.4-1.0 0.037 frequenc genotyp increas significantli accord sever cervic carcinogenesi test trend 0.0002 wherea genotyp show opposit trend test trend 0.007 compar ifn-gamma genotyp hpv statu 18-contain genotyp frequent found hpv lsil 12-contain genotyp frequent found hpv hsil compar non-13 genotyp genotyp hsil frequent infect hpv58 frequent infect hpv18 0.007 genet polymorph ifn-gamma gene associ individu suscept cervic carcinogenesi polymorph correl hpv infect diseas- type-specif manner
current avail serum biomark insuffici reliabl distinguish patient epitheli ovarian cancer eoc healthi individu metabonom studi metabol process biolog system base us h-nmr spectroscopi multivari statist biochem data gener interpret provid characterist fingerprint diseas effort examin util metabonom approach discrimin sera women eoc healthi control perform h-nmr spectroscop analysi preoper serum specimen obtain patient eoc patient benign ovarian cyst healthi women data reduct appli both unsupervis princip compon analysi pca supervis soft independ model class analog simca pattern recognit sensit specif tradeoff summar variabl us area under receiv-oper characterist roc curv addit analyz region nmr spectra most strongli influenc separ sera eoc patient healthi control pca analysi allow correct separ serum specimen patient eoc 100 premenopaus normal sampl 100 sera patient benign ovarian diseas 100 addit possibl correctli separ 97.4 cancer specimen postmenopaus control sera simca analysi us cooman's plot demonstr sera class patient eoc benign ovarian cyst postmenopaus healthi control share multivari space provid valid class separ roc analysi indic sera patient diseas identifi 100 sensit specif h-nmr region 2.77 part per million ppm 2.04 ppm origin auc roc curv 1.0 addit regress coeffici most influenti eoc sampl compar postmenopaus control lie around delta3.7 ppm due mainli sugar hydrogen load most influenti eoc sampl lie around delta2.25 ppm delta1.18 ppm find indic h-nmr metabonom analysi serum achiev complet separ eoc patient healthi control metabonom approach deserv evalu potenti novel strategi earli detect epitheli ovarian cancer
role folat metabol cancer develop topic much current interest mainten adequ folat statu tend show protect effect aberr methyl primarili hypermethyl certain gene includ tumor suppressor implic prostat cancer develop folat vitamin b12 homocystein essenti methyl group metabol dna methyl relat plasma level factor prostat cancer risk prospect studi 254 case subject 514 match control subject increas plasma level folat vitamin b12 statist significantli associ increas prostat cancer risk odd ratio 1.60 1.03-2.49 trend 0.02 folat 2.63 1.61-4.29 trend &lt 0.001 vitamin b12 highest lowest quartil increas plasma homocystein level associ reduc risk borderlin signific 0.67 0.43-1.04 trend 0.08 adjust plasma variabl bodi mass index smoke statist signific increas risk remain vitamin b12 2.96 1.58-5.55 trend 0.001 adjust folat homocystein 1.30 0.74-2.24 trend 0.17 0.91 0.51-1.58 trend 0.60 respect result suggest factor contribut folat statu protect prostat cancer contrari vitamin b12 associ 3-fold increas risk possibl folat stimul prostat cancer develop find novel explor futur studi
tumour marker ca125 import indic clinic progress women carcinoma ovari investig interv nadir ca125 valu progress defin rise ca125 time biochem progress tbp overal surviv patient treat chemotherapi diseas relat nadir ca125 valu patient &lt u/ml chemotherapi median tbp group patient nadir &lt u/ml 2436 dai group patient nadir 11-20 182 dai group nine patient nadir 21-30 dai &lt 0.001 associ similar differ overal surviv median 2968 dai group 537 dai group 537 dai group &lt 0.001 variat ca125 valu normal rang carri us inform prognost indic will us studi manag patient respons first-line chemotherapi
background angiogenesi essenti develop growth advanc solid tumor cyclooxygenas cox recogn angiogen factor variou tumor prompt studi clinic implic cox-2 express angiogenesi uterin endometri cancer patient method fifti patient underw cur resect uterin endometri cancer uterin endometri cancer cox-2 level determin enzym immunoassai local count microvessel determin immunohistochemistri result signific correl microvessel count cox-2 level uterin endometri cancer cox-2 local cancer cell stromal cell uterin endometri cancer tissu cox-2 level decreas advanc furthermor cox-2 level significantli correl vegf level uterin endometri cancer conclus vegf associ cox-2 work angiogenesi earli statu growth long-term administr cox-2 inhibitor effect suppress recurr initi uterin endometri cancer cur resect
background role select macronutri fatti acid cholesterol etiolog prostat cancer analyz us data case-control studi carri five italian area 1991 2002 patient method case 1294 men incid histolog confirm prostat cancer admit major teach gener hospit studi area control 1451 men admit acut non-neoplast condit same hospit network inform dietari habit elicit us valid food frequenc questionnair includ food group recip odd ratio confid interv estim increas level nutrient intak result direct associ prostat cancer found starch intak 1.4 highest versu lowest quintil intak 1.1-1.8 wherea invers associ emerg polyunsatur fatti acid 0.8 0.6-1.0 among polyunsatur fatti acid linolen acid 0.7 0.6-0.9 linol acid 0.8 0.6-1.0 invers relat prostat cancer six major macronutri includ same model advers effect high intak starch monounsatur fatti acid statist signific togeth protect effect polyunsatur fatti acid result consist separ strata ag bodi mass index famili histori prostat cancer conclus starch monounsatur fatti acid directli associ prostat cancer risk polyunsatur fatti acid invers associ
background frozen section diagnosi diagnost procedur assess adnex mass surgeri purpos present studi perform systemat review literatur accuraci frozen section diagnosi assess adnex mass method perform computer medlin embas search identifi regist articl publish januari 1966 june 2003 compar frozen section diagnosi ovarian patholog final histopatholog diagnosi studi calcul preval malign borderlin tumor sensit specif frozen section diagnosi us final histopatholog diagnosi refer perform calcul two wai first analysi tumor found borderlin consid malign tabl second analysi tumor found borderlin consid benign tabl result eighteen studi includ analysi diagnosi borderlin classifi malign sensit frozen section diagnosi vari specif 100 diagnosi borderlin consid benign sensit vari 100 specif vari 98.3 100 conclus accuraci frozen section diagnosi assess ovarian mass good accept sensit almost perfect specif futur studi patient prefer differ outcom well econom analysi need definit posit diagnost techniqu
object safe effect treatment need relaps ovarian cancer goal includ improv symptom enhanc qualiti life prolong surviv plethora agent current avail present difficult choic physician present effort seek examin role on agent pegyl liposom doxorubicin method roundtabl meet expert manag ovarian carcinoma held build consensu around present futur role pegyl liposom doxorubicin ovarian cancer gynecolog malign result pegyl liposom doxorubicin effect well toler relaps ovarian cancer compar topotecan phase iii random trial pegyl liposom doxorubicin show sever advantag improv qualiti life fewer sever advers event fewer dose modif hematolog support lower total cost per patient platinum-sensit patient pegyl liposom doxorubicin produc surviv advantag result prospect retrospect studi demonstr improv cardiac safeti pegyl liposom doxorubicin compar convent anthracyclin conclus base surviv toxic advantag onc-monthli administr schedul pegyl liposom doxorubicin first-choic nonplatinum agent relaps ovarian cancer pegyl liposom doxorubicin clinic applic combin regimen platinum-sensit ovarian cancer consolid/mainten therapi ovarian cancer compon first-line therapi ovarian cancer treatment gynecolog malign futur clinic trial will defin maxim role pegyl liposom doxorubicin treatment ovarian cancer gynecolog malign
object recent show level secret human leukocyt antigen-g hla-g nonclass mhc class antigen significantli elev malign effus ovarian carcinoma compar benign on object studi evalu express clinic role hla-g effus correspond solid tumor patient diagnos advanc-stage ovarian carcinoma method effus 148 correspond primari tumor metastat lesion 122 analyz us immunohistochemistri anti-hla-g monoclon antibodi result hla-g detect cancer cell 49/148 effus 33/66 primari tumor 59/122 solid metastas differ reach statist signific express effus solid metastas significantli correl 0.029 hla-g express tumor cell significantli lower effus obtain chemotherapi 0.038 presenc hla-g-posit tumor cell effus obtain prior institut chemotherapi correl better overal surviv 0.042 hla-g express primari tumor solid metastas correl clinicopatholog paramet studi conclus hla-g express signific number ovarian carcinoma anatom site reduc express hla-g post-chemotherapi effus correl improv surviv relat preferenti suscept hla-g-express cell site find suggest role hla-g prognost indic advanc-stage ovarian cancer effus
object evalu subren capsul xenograft primari ovarian tumor tissu mice develop ovarian cancer model method piec ovarian tumor specimen patient meticul graft under renal capsul femal nod/scid mice surgic remov tumor type includ papillari serou adenocarcinoma borderlin benign mucin cystadenoma granulosa cell tumor serou borderlin tumor grade mix surfac epitheli tumor transit undifferenti type 1-2 month graft retriev comparison origin tissu hematoxylin eosin h&amp immunohistochem stain carri us tissu micro-arrai cea b72.3 wt-1 oc125 keratin inhibin ck7 ck20 cam5.2 mib-1 marker result tumor tissu engraft rate comparison donor post-graft tissu show highli similar histopatholog featur +/- concord immunostain indic major preserv immunophenotyp xenograft 30-60 dai small signific increas mib-1 prolif index xenograft compar origin specimen conclus subren capsul xenograft primari human ovarian tumor scid mice retain major histopatholog immunohistochem characterist origin tissu achiev consist high engraft rate allow us xenograft tool studi wide rang ovarian tumor includ granulosa cell tumor benign borderlin malign surfac epitheli neoplasm potenti applic includ preclin test patient' tumor respons variou chemotherapeut regimen evalu novel therapeut agent analysi tumor progress cellular molecular level identif therapeut target
object estim antitumor activ 9-aminocamptothecin 9-ac patient recurr platinum- resist ovarian cancer determin natur degre toxic 9-ac cohort patient method multicent phase studi conduct gynecolog oncolog group gog patient receiv 9-ac colloid dispers microg/m 600 microg/m /dai 120 dai dai dose adjust permit toxic schedul repeat everi dai diseas progress unaccept advers event hematopoiet growth factor support us necessari result januari 1999 decemb 2000 member institut gog enrol patient two patient receiv therapi evalu median ag rang 33-81 year median four rang 1-32 cours 9-ac administ most frequent grade toxic neutropenia leukopenia gastrointestin anemia thrombocytopenia on possibl treatment-relat death four complet four partial respons overal respons rate eighteen patient stabl diseas progress respons assess conclus 9-ac dose schedul show limit activ compar agent platinum-resist ovarian primari periton cancer
introduct tradit approach patient ovarian cancer cytoreduct surgeri surgic stage through vertic midlin laparotomi laparoscopi becom integr part gynecolog surgeri debulk procedur feasibl date standard minim invas techniqu method materi twenti-five patient ovarian carcinoma underw surgic stage cytoreduct us hand-assist laparoscopi review surgic techniqu clinic outcom result twenti-five patient manag studi time frame hand-assist laparoscopi six patient appar advanc stage ovarian cancer time referr patient appar earli-stage ovarian cancer patient presum earli-stage diseas patient upstag base retroperiton lymph node involv diseas pelvic structur patient microscop diseas omentum twenti-two patient surgeri complet via hand-assist laparoscopi three case requir convers laparotomi complet debulk surgeri complic rate low three complic requir reoper hospit mean hospit stai 1.8 dai patient success hand-assist laparoscop evalu oper time variabl rang 365 min conclus hand-assist laparoscopi emploi initi manag earli advanc stage ovarian carcinoma approach allow thorough evalu periton retroperiton structur surgic cytoreduct retain advantag minim invas surgeri
object identifi valid gene up-regul ovarian cancer investig whether activ candid gene creatin kinas ckb elev pre-oper sera ovarian cancer patient compar patient benign pelvic mass normal control method micromax cdna microarrai system rna deriv pool ovarian cancer cell line normal ovari surfac epitheli cell hose us identifi differenti express gene us rna both cell line tissu obtain through laser captur microdissect lcm perform quantit pcr order valid up-regul on gene creatin kinas ckb us commerci avail enzym assai ckb activ measur pre-oper serum sampl obtain ovarian cancer patient patient benign pelvic mass well normal control statist analysi preform us unpair student's test result microarrai technolog reveal ckb gene express cancer hose ratio rna level ckb measur real-time pcr elev mean standard error 36-fold 8.4 cancer cell line compar hose cell 22.75-fold 10.45 microdissect ovarian cancer epitheli cell compar normal ovarian epitheli cell serum mean +/-standard error ckb enzym activ cancer case 24.7 u/l unit +/- 5.1 compar 9.6 u/l +/- 1.6 benign mass case 0.0088 8.5 u/l 1.7 normal control 0.0096 conclus microarrai technolog offer method identifi tumor biomark potenti clinic us data indic ckb gene express up-regul ovarian cancer cell vitro vivo ckb enzym activ significantli elev sera ovarian cancer patient includ stage diseas find suggest potenti role ckb marker earli diagnosi
background develop simpl cost-effect method detect genotyp high-risk human papillomavirus hpv us seminest polymeras chain reaction pcr revers hybrid method cervic swab hpv test collect 127 women normal cervic cytolog patient cervic lesion variou degre dna isol pcr amplif first carri us my11 my09/hmb01 primer label seminest pcr us first pcr product my11/biogp6+ primer on fifth second pcr product resolv gel electrophoresi genotyp high-risk hpv done separ us remain product high-risk hpv chip contain type-specif oligonucleotid nylon membran final result detect colorimetr chang chip under direct visual result high-risk hpv dna detect 127 women normal cervic smear cytolog 89.7 patient cervic intraepitheli neoplasia cin 96.4 patient invas cervic carcinoma multipl high-risk hpv infect detect five case hpv type most frequent type infect compris 34.5 53.6 patient cin invas carcinoma respect sampl visibl 190-bp band electrophoresi exclus show neg hybrid result method detect on two copi hpv-16 genom deriv on siha cell overal sensit hpv detect copi hpv genom specimen thirteen high-risk type twenti-four differ type hpv dna show specif hybrid cross-reaction conclus result demonstr feasibl optimist prospect simpl cheap method high-risk hpv genotyp technolog easili set routin molecular laboratori probabl great valu cervic cancer prevent program
object specif ctl respons human papillomaviru hpv antigen women cervic cancer poorli studi immunolog monitor respons central understand principl underli success immunotherapeut strategi aim studi investig hpv16 e6/e7-specif ctl immun respons group untreat hpv16-posit cervic cancer patient method peripher blood mononuclear cell untreat cervic cancer patient healthi control isol prior therapi autolog monocyt-deriv dendrit cell mddc transient transfect hpv16 express vector us on round vitro restimul target cell chromium releas assai restimul peripher blood lymphocyt result transfect monocyt-deriv dendrit cell differenti exhibit fulli matur phenotyp hpv16 transgen express translat measur rt-pcr intracellular flow cytometri respect hpv16-associ cervic cancer patient show evid specif ctl lytic activ hpv16 11/12 8/9 100 effector target ratio none hpv16-neg cervic cancer patient healthi control lysi conclus data suggest hpv-specif cytolyt immun respons detect untreat cervic cancer patient approach us dendrit cell restimul target cell enhanc immunomonitor cervic cancer patient
purpos multicent studi conduct evalu activ toxic gemcitabin patient previous treat non-squamou cell carcinoma uterin cervix patient method elig patient requir measur diseas gog perform statu 0-2 adequ bone marrow renal hepat function histolog confirm primari diagnosi mandatori patient requir receiv on prior chemotherapi regimen metastat persist recurr diseas initi dosag gemcitabin 800 mg/m weekli time three week progress diseas advers side effect prohibit therapi dose escal reduc base diseas toxic experi previou cycl result twenti-two women enter trial three patient complet follow-up assess tumor respons leav evalu patient respons patient evalu toxic median two cycl administ patient rang 1-8 overal respons rate partial respons 4.5 36.4 patient have stabl diseas median progress-free interv 2.1 month rang 0.5-12.7 overal surviv 6.5 month rang 0.6-21.9 on patient grade gastrointestin advers event rectovagin fistula format attribut underli cancer studi agent complic grade metabol derang grade hematolog toxic treatment-relat death conclus gemcitabin singl agent minim activ previous treat patient non-squamou cell carcinoma uterin cervix
object gynecolog oncolog group gog studi number drug determin activ patient previous treat squamou nonsquam cancer aris uterin cervix phase studi intraven vinorelbin initi purpos patient stage ivb recurr persist nonsquam carcinoma receiv on prior chemotherapi elig studi method elig patient measur diseas gog perform statu 0-2 adequ bone marrow liver renal function treatment consist vinorelbin mg/m dai repeat everi dai tumor measur toxic record everi treatment cycl result thirti patient enrol patient deem elig evalu two confirm partial respons 7.1 note neutropenia most common toxic experienc grade chang anemia sever seven neuropathi mild three patient sever event fatigu hypertens pulmonari chang attribut drug administr occur on two instanc conclus dose schedul assess criteria emploi vinorelbin minim activ nonsquam cancer cervix
object assess whether adequ strategi us manag cervic intraepitheli neoplasia cin hiv-posit patient method set retrospect studi hiv refer univers hospit sixti-eight hiv-infect patient undergon cervic biopsi januari 1995 march 2002 match cin ag hiv-neg patient outcom assess mean treatment strategi assess mean treatment failur immedi follow-up pap smear recurr rate long-term follow-up smear result both group patient receiv similar treatment cervic anomali hiv-posit women two time like involv margin conis hiv-neg women &lt 0.01 global two third hiv-neg patient first follow-up pap smear normal case on third hiv-posit women proport significantli differ conis &lt 0.01 same differ observ sustain follow-up hiv-infect women show recurr dysplasia like fail antivir therapi 9/44 recurr 7/12 &lt 0.01 conclus higher rate recurr observ among hiv-infect women indic cin manag difficult requir adapt guidelin hiv-posit patient hiv-infect patient associ found absenc recurr viral respons antivir therapi
object present clinic applic multispectr imag colposcop system mi colposcopi method mi colposcopi perform 123 enrol women acet acid applic sequenti imag captur analyz store automat direct biopsi taken distinct mark acet acid-respons tissu area indic monitor real-time assess curv intens backscatt light ibsl time perform blind biopsi taken non-acetowhiten area histolog find correl mi colposcopi result compar convent colposcopi pap test result result acet acid-tissu interact result tempor spatial alter light scatter properti abnorm tissu analyz shape ibsl curv relax time time take ibsl decai 1/e peak valu chang accord underli lesion sever cin lesion lead higher maximum ibsl longer durat acetowhiten lead increasingli delai exponenti decai ibsl curv compar histolog examin mi colposcopi 1.7 fals-diagnost rate pap test convent colposcopi 24.4 fals-diagnost rate respect tripl exponenti function creat pseudocolor imag compris grade map lesion frequent repres durat/degre induc alter conclus improv diagnost inform gain record optic inform narrow spectral rang high spatial resolut mi colposcopi us diagnosi uterin cervix patholog condit differenti cin lesion
object twelv cycl singl-agent paclitaxel demonstr prolong progress-free surviv women advanc ovarian cancer achiev clinic complet respons primari platinum/paclitaxel chemotherapi regimen trial conduct compar toxic diseas-free interv cycl cycl paclitaxel consolid patient treat intens three-drug front-line regimen carboplatin paclitaxel gemcitabin method cytoreduct surgeri ovarian cancer patient receiv primari chemotherapi carboplatin auc dai paclitaxel 175 mg/m dai gemcitabin 800 mg/m dai dai treatment repeat everi dai cycl first patient group receiv three addit cycl paclitaxel 175 mg/m everi dai second set patient group receiv three cycl paclitaxel 175 mg/m everi dai receiv nine addit cycl paclitaxel 135 mg/m everi dai consolid therapi chang cycl cycl consolid therapi group made publish result gog 178 result group patient complet three cours consolid therapi on patient experienc grade neutropenia two patient exhibit both grade neutropenia thrombocytopenia grade neuropathi develop patient group patient intend receiv total cycl paclitaxel consolid abl complet program grade 3-4 neutropenia anemia popul patient develop grade thrombocytopenia grade neuropathi develop patient random experi median progress-free interv week group week group conclus singl-agent paclitaxel consolid therapi administ cycl first-line carboplatin paclitaxel gemcitabin induct therapi consider risk develop moder sever peripher neuropathi
object aim studi elucid clinicopatholog immunohistochem prognost factor patient ovarian carcinosarcoma treat radic surgeri postop chemotherapi method 6-year period nine patient ovarian carcinosarcoma refer institut tissu block review section contain both carcinomat sarcomat element stain epitheli membran antigen ema vimentin vascular endotheli growth factor vegf cd45ro c-erbb-2 p53 cd34 ki67 s100 estrogen progesteron receptor histolog immunohistochem find well clinic characterist correl progress-free interv overal surviv result four homolog five heterolog carcinosarcoma five patient earli stage diseas seven patient optim debulk patient treat anthracyclin-base chemotherapi surgeri regard immunohistochemistri specimen neg cd34 c-erbb-2 estrogen progesteron receptor express five tumor overexpress p53 four specimen demonstr posit stain ki67 reactiv vegf cd45ro observ four two tumor specimen respect median overal surviv 32.9 month statist differ earli advanc stage median time progress 13.5 month p53 overexpress demonstr trend better overal surviv conclus p53 overexpress seem influenc overal surviv due small number patient studi safe conclus drawn despit predomin earli stage patient favor influenc overal surviv aggress surgic cytoreduct follow anthracyclin-base treatment cornerston multimod approach
object associ ca125 regress rate initi respons chemotherapi prognosi remain unclear examin associ ca125 regress neoadjuv chemotherapi nac prognosi method fifti patient advanc ovarian cancer tnm classif tiiic receiv initi nac undergo signific cytoreduct surgeri select retrospect analysi exclud clear cell carcinoma mucin adenocarcinoma put cisplatin-resist patient regress coeffici calcul us ca125 level measur dai nac dai dai normal ca125 level &lt iu/ml dai standard surgeri respond defin regress coeffici -0.039 greater case nonrespond regress coeffici -0.039 case result 3-year surviv rate case 59.3 stratifi regress coeffici ca125 level 3-year surviv 70.5 respond 43.3 nonrespond univari analysi identifi regress coeffici ca125 signific prognost factor overal surviv 0.012 log lank test residu tumor standard surgeri nac absolut ca125 level signific prognost factor conclus base ca125 regress rate possibl stratifi tiiic ovarian serou adenocarcinoma case good prognosi surviv poor prognosi regress coeffici ca125 level greater -0.039 predict good 3-year surviv subsequ radic surgeri
object function assai tumor suppress loss heterozygos point tumor suppressor gene tsg cervic cancer chromosom 11q23 evalu igsf4 put tsg locat region promot methyl gene silenc cell line cervic tissu method igsf4 express detect both rt-pcr northern blot analysi methyl map igsf4 promot region gener cell line base bisulfit-genom sequenc us seven nest-pcr primer set cover cpg site methyl fingerprint primari cervic tissu evalu denatur high perform liquid chromatographi result 4.4-kb mrna cell line consist rt-pcr result both cell line primari cervic tissu igsf4 express 6/11 cell line 6/8 tissu seven normal cervic epithelia cell line igsf4 silenc associ promot hypermethyl methyl statu region cover -18 cpg site correl most strongli express point exist unmethyl core igsf4 promot cell line express igsf4 unmethyl core span approxim 180 immedi upstream atg site primari tissu methyl detect 15/23 specimen none seven normal cervic epithelia conclus data strongli suggest igsf4 tsg gene silenc aberr hypermethyl contribut develop
object uterin carcinosarcoma uncommon highli aggress neoplasm frequent recur surgic treatment adjuv chemo-radiotherapi patient recurr diseas respond poorli salvag chemotherapi irradi therapeut option requir patient metastat diseas clinic evid show effect tyrosin kinas inhibitor sti571 c-kit-posit gastrointestin tumor role cox-inhibitor chemotherapi-associ colorect cancer patient success therapeut possibl anti-her2 therapi metastat breast carcinoma encourag studi express c-kit cox-2 her-2/neu uterin carcinosarcoma method analyz express cox-2 c-kit her-2/neu uterin carcinosarcoma correl clinic outcom diseas-free interv actuari surviv rate point studi result high stain intens cox-2 observ case 33.3 c-kit express case 16.7 her-2/neu case 29.2 patient cox-2-posit tumor significantli poorer diseas-free interv surviv 0.01 0.05 respect patient c-kit-posit tumor earli stage diseas spite surviv significantli better c-kit-neg case her-2/neu express show correl clinic outcom conclus c-kit cox-2 her-2/neu express differ proport uterin carcinosarcoma cox-2 express strong indic unfavor prognosi result warrant studi evalu possibl role molecularli target cancer therapi cox-2 inhibitor patient uterin carcinosarcoma role c-kit express consequ hypothet us sti571 test larger seri
object standard primari treatment local advanc cervix cancer radiat concomit platinum-base chemotherapi incomplet local control appear distant diseas herald poor surviv warrant evalu primari strategi paclitaxel carboplatin activ agent recurr cervic carcinoma potent synergist vitro radiosensit cytotox weekli schedul studi done determin maximum toler dose mtd dose-limit toxic dlt weekli paclitaxel/carboplatin chemoradiotherapi local advanc cervix cancer method women primari previous untreat squamou cell adenocarcinoma cervix figo stage iva neg para-aortic lymph node adequ organ function perform statu elig pelvic week--180 cgy/dai four-field follow two brachytherapi applic point low dose rate ldr high dose rate hdr concurr weekli paclitaxel mg/m carboplatin start auc 1.5 escal three-patient cohort auc 0.5 max auc 3.5 dose escal follow 4-week observ period toxic grade iii-iv toxic prompt three addit patient per dose level second event defin dlt administ concurr brachytherapi result fifteen patient enrol treat four dose level dlt reach median ag year rang 23-70 stage ib2 iib iiia iiib median treatment time dai rang 55-79 fourteen patient receiv brachytherapi ldr hdr on receiv extern due cervic stenosi median number weekli cycl seven rang 6-7 on dose drop on patient grade thrombocytopenia on grade iii anc observ dose level auc 2.0 three addit patient dose level auc 3.0 two grade iii-iv anc toxic observ two patient dlt nine patient grade anemia on patient grade iii anemia grade iii/iv nonhematolog toxic rare 1/15 gi-nausea/vomit 1/15 pneumonia 1/15 hypokalemia mtd carboplatin auc 2.5 paclitaxel mg/m median follow-up month three patient recur two di estim 2-year pf conclus weekli paclitaxel carboplatin chemoradi feasibl activ mtd phase trial mg/m auc 2.5 respect
object studi conduct explor associ cpg island hypermethyl tumor-associ gene polymorph methyl group metabol enzym uterin cervic cancer method analyz cpg island hypermethyl gene apc cdh1 cox2 dapk fhit gstp1 hltf1 hmlh1 mgmt p14 p16 rassf1a runx3 thb1 timp3 associ methylen-tetrahydrofol reductas mthfr c677t a1298c methionin synthas a2756g polymorph korean women uterin cervic cancer result uterin cervic cancer sampl least on gene methyl averag number methyl gene lower patient heterozyg genotyp mthfr common homozyg genotyp differ signific mthfr 677 genotyp significantli associ decreas promot hypermethyl -methylguanin dna methyltransferas mgmt 0.22 confid interv 0.07-0.70 0.011 howev mthfr c677t a1298c a2756g polymorph associ increas risk uterin cervic cancer conclus find suggest possibl interact epigenet genet factor uterin cervic cancer
object examin preval human papillomaviru chlamydia trachomati dna cervic sampl among women normal abnorm cervic cytolog plata argentina method two hundr seventi-nine women 200 cervic neoplasia icc women normal cytolog provid cervic sampl detect hpv trachomati dna pcr-base assai result hpv dna increas cervic lesion sever rang among women normal cytolog 99-100 among women hsil icc trachomati dna preval increas low level women normal cytolog hsil uncommon among icc patient among women normal cytolog trachomati preval higher hpv dna posit 12.5 hpv dna neg women 10.9 differ signific conclus hpv preval gener popul slightli higher report develop countri trachomati dna posit associ higher risk both lsil hsil lesion icc
object describ feasibl result total laparoscop radic hysterectomi intraop sentinel lymph node identif patient earli cervic cancer method march 2001 octob 2003 patient figo stage cancer cervix underw surgic treatment through laparoscop rout patient underw laparoscop sentinel node identif preoper lymphoscintigraphi technetium-99 colloid albumin inject around tumor intraop lymphat map isosulfan blue dye laparoscop gamma probe follow systemat bilater pelvic lymphadenectomi laparoscop type type iii hysterectomi result mean 2.5 sentinel node per patient rang 1-4 detect mean 2.33 node per patient gamma probe mean per patient blue inject combin detect rate 100 most frequent local node interiliac region histopatholog examin sentinel node includ cytokeratin immunohistochem analysi show metastasi microscop nodal metastas found mean number resect pelvic node 18.6 per patient rang 10-28 oper perform entir laparoscopi patient case laparotomi convers record mean durat oper 271 min rang 235-300 mean blood loss 445 rang 240-800 mean length stai 5.25 dai rang 3-10 major intraop complic occur median follow-up month rang 5-34 patient free diseas conclus studi show feasibl combin laparoscop intraop sentinel node map laparoscop radic surgeri context minim invas surgeri manag patient earli cervic cancer
object chemoradi base cisplatin standard treatment local advanc cervic carcinoma howev optim schedul dose still establish studi conduct determin maximum-toler dose mtd cisplatin daili administr pelvic radiotherapi method fourteen patient local advanc cervic carcinoma requir postop regist low dose cisplatin given daili concurr cisplatin dose start 6.0 mg/m /dai increment 0.5 mg/m /dai deliv gy/dai total dose mtd defin dose level immedi caus dose-limit toxic dlt on-third treat patient result twenti-five patient treat maximum six escal dose level 22/25 patient cisplatin administ continu plan interrupt mtd determin mg/m dlt indic onset neutropenia conclus daili cisplatin mg/m /dai well-toler radiosensit cervic carcinoma patient
object evalu prognost factor impact surviv women sex cord stromal tumor ovari scst method case identifi tumor registri databas three academ institut 1975 2003 patient characterist surgic treatment adjuv therapi patholog follow-up inform collect hospit chart clinic record kaplan-meier cox proport hazard analys us identifi predictor outcom result eighti-three women median ag year scst ovari includ granulosa sertoli-leydig cell tumor identifi fifti-on stage stage stage iii stage patient unstag median 5-year diseas-specif surviv women stage i-ii iii-iv 180 month compar month respect 0.012 furthermor ag &lt 0.003 premenopaus statu 0.013 tumor size &lt 0.003 lack lymph node invas &lt 0.0005 absenc residu diseas 0.002 signific predictor improv surviv patient receiv adjuv treatment chemotherapi impact surviv 0.11 twelv stage patient underw fertil-spare surgeri three recurr multivari analysi ag &lt smaller tumor size absenc residu diseas remain independ prognost factor median follow month rang 1-310 conclus ag &lt smaller tumor size absenc residu diseas import predictor improv surviv patient scst ovari
background granulosa cell tumor gct ovari rare hormon activ neoplasm character endocrin manifest indol cours late relaps case report case prolong histori ovarian gct manag primarili repeat surgic resect conclus case illustr benefit cytoreduct surgeri manag recurr diseas us serum tumor marker help guid therapi import extend follow-up
background positron emiss tomographi comput tomographi pet/ct potenti role detect locat recurr ovarian cancer precis tumor locat surgic treatment difficult ow limit tumor size post-surgic anatom modif surgic gamma probe becom increas popular recent year develop sentinel node map improv tumor detect facilit resect occult metastas case report describ first case laparoscop resect occult metastasi us combin fdg-pet/ct imag fusion intraop fdg-sensit probe patient recurr ovarian cancer conclus fdg-sensit probe combin preoper pet/ct imag fusion help detect occult metastasi guid laparoscop excis
background small percentag germ cell tumor known famili sever report describ famili case testicular germ cell tumor howev few report germ cell tumor occur both male femal same famili case present famili three children two femal on male previous healthi develop germ cell malign first sibl diagnos malign teratoma ovari second on dysgerminoma involv both ovari male on both embryon carcinoma seminoma testicl conclus case report suggest possibl associ germ cell tumor both ovari testi consid
background serou psammocarcinoma form ovarian carcinoma character massiv psammoma bodi format invas low-grade cytolog featur report bilater case serou psammocarcinoma review literatur order delin clinic patholog prognost featur rare neoplasm case histori 66-year-old white woman admit institut volumin abdomino-pelvic mass suspect leiomyoma uteru abdomin comput tomographi scan reveal heavili calcifi abdominopelv mass cystic area origin lesion unclear divers scan comput tomographi elev serum ca-125 level suggest eventu ovarian neoplasm patient underw exploratori laparotomi intraoperatori find show two ovarian calcifi lesion surfac omentum cover white nodul patholog find consist serou psammocarcinoma invas implant omentum conclus serou psammocarcinoma rare form ovarian carcinoma case report literatur patient's ag rang year prognost factor suggest neoplasm favor prognosi usual serou carcinoma import differenti two neoplasm pelvic mass calcifi leiomyoma
carotid bodi tumor cbt rare entiti consid evalu everi later neck mass object studi compar demograph data complic evolut patient treat institut retrospect studi made patient cbt treat institut 1982 2002 review demograph characterist clinic featur surgic approach complic women significantli predomin 96.9 femal male ratio 31.2 ag rang mean 50.2 fifti-four per cent patient live altitud higher 2200 sea level most common chief complaint painless neck mass 78.7 patient malign tumor famili histori cbt both side similarli affect four tumor group shamblin's class class class iii six tumor undetermin shamblin's class infer medic record fifti-three patient receiv treatment 86.8 surgeri 11.3 radiotherapi 1.9 radiotherapi surgeri three patient 6.3 underw vascular reconstruct patient neurolog deficit observ surgeri minor complic occur five 10.6 patient median follow-up month on patient di caus relat cbt rest remain diseas-free asymptomat found overwhelm predomin women open possibl deal differ diseas femal latin popul most tumor shamblin's class iii cbt earli surgic manag recommend avoid neurolog deficit due shamblin's class iii tumor
background ovarian tumor uncommon import childhood neoplasm procedur review record pediatr patient present three pediatr referr center 1980 2003 result thirti patient benign tumor thirti-seven patient malign tumor immatur teratoma seven malign mix germ cell tumor seven juvenil granulosa cell tumor five dysgerminoma two endoderm sinu tumor two serou papillari cystadenocarcinoma on small cell carcinoma on anaplast sex-cord tumor on undifferenti sarcoma half present abdomin pain forti-six percent abdomin mass time present sign symptom includ poor appetit urinari symptom/urinari infect menstrual chang weight loss precoci puberti note seven patient torsion patient benign tumor two patient both torsion acut append neoplasm incident find patient conclus fifti-five percent ovarian tumor present center malign pain most common symptom presenc abdomin mass frequent symptom non-specif almost neoplasm present unilater mass rare metastat diagnosi ovarian tumor consid differenti diagnosi young girl abdomin pain mass non-specif symptom
antiangiogen gene transfer potenti efficaci protein-base therapi pharmacotherapi control solid tumor growth invas metastasi sustain antiangiogen effect vector capabl long-term express vector-associ immun toxic advantag present studi evalu potenti recombin adeno-associ viru-2 raav encod human solubl fm-like tyrosin kinas receptor sflt-1 function both sequest vascular endotheli growth factor vegf form inact heterodim membran-span vegf receptor vitro vivo result indic signific growth inhibitori activ transgen factor human umbil vein endotheli cell prolifer assai vitro protect growth angiogenesi-depend human ovarian cancer cell line skov3.ip1 xenograft vivo increas diseas-free surviv stabl express secretori factor transgen persist confirm immunohistochemistri situ hybrid analys respect increas therapeut effect both growth index implant tumor cell tumor-free surviv correl increas dose vector us studi indic raav-mediat sflt-1 gene therapi feasibl approach inhibit tumor angiogenesi particularli adjuv/therapi
replic-compet adenovirus ad's emerg promis modal treatment cancer select replic viral agent tumor lead improv efficaci nonrepl ad's due inher abil multipli lyse spread surround cell previous shown e1b kda-delet adenoviru ykl-1 exhibit tumor-specif replic cell lysi cytolyt effect reduc comparison wild-type adenoviru increas oncolyt potenc ykl-1 reintroduc death protein adp gene under control cmv mlp promot region ykl-1 gener ykl-cadp ykl-madp ad's respect adp 11.6 kda protein encod transcript unit requir kill adenoviru-infect cell effici howev date mechan adp mediat cell death clearli defin studi report adp-overexpress markedli enhanc cytolyt effect 100-fold tumor cell line test increas cytopath effect normal skin fibroblast moreov plaqu size form ykl-cadp substanti larger ykl-1 indic enhanc cell lysi tunel termin deoxynucleotidyl transferas-mediat dutp nick-end label assai annexin-v/pi doubl stain indic adp-mediat cytotox larg driven apoptosi final ykl-cadp adenoviru show superior antitumor effect ykl-1 ykl-madp c33a cervic hep3b hepatoma xenograft tumor model taken togeth line evid demonstr newli gener adenoviru express adp under cmv promot induc effici tumor-select cell lysi critic ad therapeut valu replic adenoviru us cancer gene therapi
type insulin-like growth factor receptor igf1r overexpress prostat cancer mediat prolifer motil surviv prostat cancer harbor inactiv pten mutat enhanc akt phosphoryl activ princip antiapoptot pathwai downstream igf1r call question valu igf1r target tumor aim current studi assess effect igf1r gene silenc prostat cancer cell lack function pten protein human du145 lncap pc3 prostat cancer cell transfect igf1r small interf rna induc signific enhanc apoptosi inhibit surviv pten wild-type du145 pten mutant lncap pc3 attribut attenu igf signal via akt erk p38 both du145 pc3 igf1r knockdown led enhanc sensit mitoxantron etoposid nitrogen mustard ioniz radiat sensit paclitaxel 5-fluorouracil damag dna suggest chemosensit result impair dna damag respons addit remov apoptosi protect result support concept igf1r target prostat cancer indic pten loss doe render tumor cell refractori strategi
thymidyl synthas target cancer therapi year result prolong extens drug develop program specif inhibitor clinic practic develop polyglutamat inhibitor raltitrex tomudex zd1694 zd9331 ration design third-gener specif inhibitor doe requir polyglutam activ develop base dual rational increas efficaci overcom potenti resist due reduc express folylpolyglutam synthetas fpg whilst potenti reduc toxic associ polyglutam drug retent normal tissu preclin studi shown transport ubiquit express reduc folat carrier well alpha-folat receptor overexpress cancer especi ovarian vivo studi demonstr broad rang activ lead extens phase program sever administr schedul whilst target individu tumor type larg number phase monotherapi combin studi undertaken overal activ most promis particularli platinum-refractori relaps ovarian pancreat gastric cancer role treatment diseas import especi patient select basi folat transport fpg statu true potenti drug remain determin
efficaci weekli paclitaxel androgen-independ prostat cancer addict cytotox anthracyclin deriv led determin safeti efficaci weekli schedul paclitaxel epirubicin octob 2000 novemb 2002 patient enrol studi patient characterist includ median ag year rang 68-77 adequ hepat cardiac renal bone marrow function ecog perform statu 1-2 prior chemotherapi patient receiv hormon manipul seven patient receiv prior palli radiat therapi regimen consist paclitaxel mg/m2 i.v infus epirubicin mg/m2 bolu everi week treatment continu month diseas progress unaccept toxic observ studi prostat-specif antigen psa monitor respons defin reduct psa level confirm week later thirti-on patient evalu toxic object respons seventeen patient declin psa level last week median time psa progress median durat psa respons approxim 5.5 month ten patient measur diseas confirm object respons on complet respons partial respons thirteen symptomat patient improv pain median time diseas progress 7.6 month median surviv 12.9 most promin grade toxic revers myelosuppress fatigu nausea vomit diarrhea peripher edema minim evid cardiac toxic record alopecia frequent revers patient conclud despit small sampl size studi demonstr combin weekli paclitaxel epirubicin well-toler regimen androgen-independ prostat cancer result impli combin agent weekli schedul clinic potenti prostat cancer treatment
us anthracyclin anticanc drug doxorubicin daunorubicin limit thought iron-base oxygen radic-deriv dose-depend cardiotox anthracyclin dna topoisomeras topo poison known iron-mediat format reactiv oxygen speci ro anthracyclin topo inhibitori effect respons cell growth-inhibitori effect experi test two altern carri us cho-deriv cell line dzr highli resist dexrazoxan through thr48iie mutat topo iialpha clinic us cardioprotect agent dexrazoxan like exert cardioprotect effect through chelat abil hydrolysi product adr-925 analog edta dexrazoxan cell growth inhibitor act through abil inhibit catalyt activ topo dzr cell line allow examin cell growth-inhibitori effect doxorubicin daunorubicin presenc dexrazoxan confound effect dexrazoxan inhibit cell growth growth-inhibitori effect neither doxorubicin nor daunorubicin affect pretreat dzr cell dexrazoxan contrast under similar condit dexrazoxan strongli protect rat cardiac myocyt doxorubicin-induc lactat dehydrogenas releas conclus anthracyclin inhibit growth dzr cell through gener iron-mediat format ro
human papillomaviru hpv relat cervic cancer viru shown essenti induct mainten malign phenotyp cervic cancer report design hammerhead ribozym rz170 specif target hpv16 e6e7 transcript result demonstr rz170 cleav hpv16 e6e7 transcript effect high specif transfect hpv16 posit cervic cancer cell caski ribozym reduc express hpv16 mrna inhibit cell growth both vitro vivo percentag apoptosi cell increas found rz170 reduc express viral protein cellular c-myc bcl-2 protein increas express p53 protein like ribozym inhibit cervic cancer cell growth reduc express hpv16 e7gene alter express p53 c-myc bcl-2 led apoptosi cancer cell found caski cell transfect rz170 show increas sensit cisplatin radiat studi demonstr potenti rz170 treat cervic cancer possibl us combin therapeut strategi involv ribozym chemotherapi radiotherapi
germ cell tumor gct most common genitourinari malign men ag year therapi ultim success patient howev signific morbid mortal associ adjuv treatment relaps molecular marker predict treatment respons poor outcom immedi clinic benefit adjuv treatment select reserv patient higher risk relaps patient most like respond treatment order identifi potenti prognost molecular marker evalu 118 gct microsatellit instabl msi loss heterozygos loh msh2 immunostain identifi tumor associ relaps poor outcom initi surgic medic radiat therapi msi marker low msh2 stain associ relaps loh absenc msi high msh2 stain twenti-five percent gct exhibit genet instabl microsatellit marker msi+ tumor exhibit loh absenc msi loh tumor exhibit decreas absent msh2 immunostain low msh2 stain tumor thirti-six patient relaps patient msi+ low msh2 stain tumor on patient loh tumor patient high msh2 stain loh tumor relaps distinct gct subpopul identifi detect msi loh mmr express associ differ clinic outcom mmr defici testicular gct increas frequenc msi increas associ tumor recurr compar gct intact mmr system loh absenc msi
metastat cervic cancer remain clinic problem develop effici treatment modal optim us chemo- radiotherapi requir better understand impact regul cell surviv apoptosi issu insuffici explor human papillomaviru hpv protein present cervic cancer target p53 tumor suppressor protein degrad studi role p53 mediat cytotox effect chemotherapi compound siha cervic cancer cell carri wild type p53 hpv16 genom stabli transfect domin neg p53 ddp53 ectop hpv16 order inhibit p53 function effect chemotherapi drug cell compar effect cell retain endogen residu p53 activ twenti-ight drug reduc amount mrna induc mark p53 activ clonogen cell surviv experi presenc ddp53 ectop increas decreas cytotox depend drug decreas mrna necessari suffici event p53 activ chemotherapi impact p53 clonogen cell surviv vari 0-60 indic p53 plai import crucial role respons chemotherapi find chemosensit vari depend p53 statu clinic implic earli stage cervic cancer cell usual carri p53 wherea p53 mutat frequent found advanc diseas
object aim multicent feasibl studi determin toxic profil antitumor activ gemcitabin plu oxaliplatin combin second-line treatment platinum plu paclitaxel resist/refractori advanc ovarian cancer method twenti patient receiv 30-60-min infus gemcitabin week week follow 120-180 min infus oxaliplatin everi week dose us 000 130 mg/m respect seventeen case total platinum resist platinum refractori result grade 3/4 thrombocytopenia occur 14/20 case symptomat case patient requir platelet transfus patient receiv hydrocortison dose- limit toxic thrombocytopenia combin grade 3/4 neutropenia observ 8/20 case sepsi regist five patient treat recombin erythropoietin becaus grade anemia case receiv g-csf prophylact first cycl overal respons rate combin term antitumor activ 9-51 conclus combin gemcitabin oxaliplatin us schedul gave rise moder/sever toxic profil feasibl growth factor us gemcitabin administ lower dose antitumor activ combin insuffici reward result toxic profil howev equival drug us platinum refractori resist patient
object investig immun profil patient resect duke' stage colorect cancer crc receiv adjuv therapi edrecolomab mo17-1a first-line 5-fluorouracil 5-fu -base chemotherapi patient method patient receiv dose mo17-1a week 5-fu/leucovorin 5-fu/levamisol month respect peripher blood collect postop month therapi initi peripher blood mononuclear cell test autolog mix lymphocyt reaction amlr natur killer lymphokin-activ killer lak cell activ serum cytokin quantifi elisa result fifti-two patient enter studi postop exhibit decreas level interleukin interferon-gamma il-12 granulocyt-macrophag coloni-stimul factor il-15 low cellular immun respons amlr nk- lak-cytotox increas level il-1beta tumor necrosi factor-alpha il-6 il-10 prostaglandin four month therapi patient receiv edrecolomab demonstr enhanc amlr lak activ increas serum level cytokin regul respons reduc level acut-phase cytokin immun suppressor compar patient treat convent chemotherapi conclus postop adjuv therapi edrecolomab restor vivo defici immun respons patient resect duke' crc despit clinic ineffect recent random adjuv trial result suggest immunolog studi combin edrecolomab chemotherapi requir
platinum/taxan regimen induc high respons rate prolong surviv women ovarian cancer recurr howev respons second-line chemotherapi limit pegyl liposom doxorubicin doxil/caelyx [pld] liposom anthracyclin indic second-line treatment platinum- paclitaxel-refractori ovarian cancer respons rate rang nonrandom trial patient popul larg phase random trial singl-agent pld topotecan similar efficaci overal respons rate pld-treat patient significantli improv overal surviv compar topotecan pronounc advantag platinum-sensit patient anoth random trial report pld paclitaxel compar regard respons rate progress-free surviv overal surviv regardless degre platinum sensit addit nonrandom trial pld combin activ agent result respons rate rang pld gener well toler side-effect profil compar favor commonli us chemotherapeut agent clinic set proper dose monitor enhanc toler preserv efficaci versatil agent ovarian cancer
pharmacoeconom analys us greater frequenc clinic oncolog trial analys provid guidelin priorit compet intervent alloc health care resourc particularli decid whether us drug higher acquisit cost liposom anthracyclin compet treatment liposom anthracyclin nonliposom chemotherapi agent similar activ pharmacoeconom analys data clinic trial patient kaposi's sarcoma determin overal cost achiev object respons substanti lower pegyl liposom doxorubicin doxil/caelyx [pld] liposom daunorubicin daunoxom [dnx] addit econom analys patient ovarian cancer show pld lower overal treatment cost topotecan becaus administ frequent requir fewer intervent toxic decis alloc health care resourc liposom anthracyclin treatment includ consider cost-effect potenti cost save ow improv toler
goal resist cisplatin main reason treatment failur ovarian cancer apoptosi main mechan action most cancer chemotherapeut agent apoptosi-associ protein express cisplatin-sensit a2780 coc1 -resist a2780/ddp coc1/ddp ovarian cancer cell line well effect caspas-3 activ cell studi revers transcriptas polymeras chain reaction western blot analysi method apoptot ratio a2780 coc1 a2780/ddp coc1/ddp cell treatment cisplatin measur flow cytometri result express bcl-2 bcl-x a2780/ddp coc1/ddp cell significantli higher a2780 coc1 cell respect express bax bcl-xs differ cisplatin-resist -sensit cell caspas-3 activ reduc markedli apoptot ratio significantli lower a2780/ddp coc1/ddp cell a2780 coc1 cell treatment cisplatin conclus conclud overexpress antiapoptot protein bcl-2 bcl-x down-regul caspas-3 activ associ cisplatin resist human ovarian cancer
enzymat activ cystein peptidas cathepsin --associ carcinogenesi control specif inhibitor studi object effect enhanc taxol cisplatin patient pretreat vitamin determin level cathepsin sera patient ovarian cancer activ cystein peptidas inhibitor cpi serum patient ovarian cancer noncancer patient measur us fluorogen substrat befor routin anticanc chemotherapi complementari combin chemotherapi vitamin cat activ significantli higher patient sera ovarian cancer non-cancer patient 0.0001 pound sterl result show inhibitori activ cpi complex form significantli decreas 4.6 meu/mg protein group non-cancer patient 0.7 meu/mg protein group patient ovarian cancer &lt 0.0001 supplement vitamin cycl therapi toxic drug caus decreas cystein peptidas activ 2.8-fold patient 0mg vitamin per dai given comparison control 6-fold third cours cpi dcpi complex increas 3-fold 2.3 fold respect compar group patient vitamin administ observ vitamin administ patient ovarian cancer period anticanc drug therapi cours decreas cystein peptidas activ increas enzym-inhibitor complex level
previou studi laboratori show liver -fabp intestin-fabp upregul prostat cancer cell wherea adipos-fabp epiderm-fabp down regul cancer cell compar normal cell tissu cultur biopsi sampl da 2001 shown block express l-fabp result remark effect apoptosi cell prolifer prostat cancer cell line anoth studi show induct a-fabp inhibit prolifer 145 prostat cancer cell desanti journal experiment therapeut oncolog 91-100 2004 caus downregul l-fabp transcript level suggest correl express a-fabp l-fabp prostat cancer cell high express a-fabp associ downregul l-fabp vice versa studi examin mechan l-fabp antisens regul prolifer apoptosi prostat cancer cell line us human cdna arrai blot custom dna microarrai explor differenti express gene 145 prostat cancer cell treat l-fabp antisens oligonucleotid gene differenti express confirm us quantit rt-pcr gene correl prolifer downregul antiprolif gene upregul respons antisens l-fabp suggest possibl us antisens odn therapeut agent prostat cancer futur
background littl known differ concern men women prior undergo diagnost test cancer method conveni sampl 129 outpati complet survei result statist signific differ found male femal patient howev patient evalu gender-specif cancer report significantli &lt .01 higher mean score concern relat sexual reproduct abil intim relationship almost half patient report receiv enough inform befor procedur conclus men women similar concern howev signific differ concern patient undergo procedur gender-specif versu non-gender-specif cancer patient report inadequ procedur inform suggest improv need commun health educ effort
background cervic cancer incid rate higher among vietnames american women among race/ethnic group unit state high rate cervic cancer associ low rate papanicolao pap test adher method twenti-five qualit interview focu group conduct vietnames women result interview focu group reveal unanticip inform sociocultur influenc women's belief risk factor cervic cancer data util develop cultur appropri outreach materi conclus engag target commun enabl develop cultur appropri materi address cervic cancer risk factor encourag pap test adher
approxim 520 women will diagnos carcinoma uterin cervix 2004 result signific mortal definit adjuv radiat therapi remain critic compon treatment both local distant recurr occur recent addit chemotherapi help reduc recurr improv surviv albeit cost increas toxic especi patient requir extend-field treatment agent amifostin ethyol medimmun inc gaithersburg possess cytoprotect radioprotect properti help amelior toxic report review updat rational current experi amifostin treatment carcinoma uterin cervix data suggest benefit patient pelvic malign receiv amifostin befor chemotherapi radiat subcutan administr efficaci toxic intraven rout ongo trial will like provid data role amifostin treatment carcinoma uterin cervix especi whether administr subcutan amifostin befor both chemotherapi/radiat therapi will translat reduct acut late toxic
platinum compound long plai role treatment gynecolog cancer singl-agent cisplatin carboplatin shown activ endometri cancer recent studi investig varieti platinum-base combin cervic cancer chemotherapi us primarili treat advanc recurr diseas agent proven singl-agent activ set includ cisplatin ifosfamid doxorubicin number cisplatin-base combin therapi under clinic investig varieti cisplatin-base combin us ovarian cancer chemotherapi recent studi investig substitut carboplatin oxaliplatin cisplatin addit paclitaxel review will examin recent clinic data us platinum-base chemotherapi treatment gynecolog cancer
current standard care ovarian cancer complet surgic cytoreduct follow adjuv postop platinum-base chemotherapi taxan frequent combin platinum compound adjuv chemotherapi set whether given combin sequenti produc greater progress-free overal surviv histor combin regimen becaus treatment ovarian cancer reli chemotherapi articl review evid correl chemotherapi deliv full dose schedul fdo patient outcom meta-analys suggest dose intens cisplatin carboplatin correl surviv howev find hypothesi-gener analys confirm prospect trial addit increas dose cisplatin certain threshold recommend ovarian cancer becaus greater toxic higher dose platinum compound deliv dose intens taxan us singl agent shown correl patient outcom ad taxan platinum compound appear both attenu toxic platinum compound facilit deliveri fdo chemotherapi literatur ovarian cancer clear consensu benefit maintain fdo chemotherapi clinic studi especi propos trial dose-dens carboplatin paclitaxel combin provid stronger evid effect fdo chemotherapi ovarian cancer
hypokalem paralysi medic emerg due risk cardiac arrhythmia respiratori failur rhabdomyolysi besid supplement patient kcl hasten recoveri astut physician search underli caus avoid miss treatabl curabl disord report elderli korean man present mark limb paralysi myalgia mild hypertens prostat cancer treat orchiectomi hormon therapi year previous major biochem abnorm hypokalemia 1.7 mmol/l associ high renal wast metabol alkalosi hco3- 42.6 mmol/l low plasma renin activ low aldosteron concentr normal cortisol concentr point state pseudohyperaldosteron review drug histori patient reveal consum eight pack 100 ml/pack korean herbal tonic daili treat prostat cancer past month signific amount glycyrrhiz acid 0.23 mg/ml activ ingredi licoric detect tonic discontinu herbal tonic along kcl supplement achiev recoveri week complementari/altern medicin cancer contain licoric kept mind caus hypokalemia cancer patient
object studi correl prostat-specif membran antigen psma prostat-specif antigen psa express gleason score prostat carcinoma method monoclon antibodi epitop psma extracellular domain prepar express psma prostat carcinoma determin immunohistochem stain correl express gleason score statist analyz compar psa result eight hybridoma cell line secret monoclon antibodi specif psma prepar psma express level posit correl gleason score poorli differenti prostat carcinoma express intens psma higher medium-and well-differenti prostat carcinoma &lt 0.01 howev correl level psa express gleason score 0.05 conclus psma express level us us surrog marker gleason grade prostat carcinoma suitabl target psa antibodi mediat immunotherapi poorli differenti prostat carcinoma usual sensit hormon therapi
background non-genom mechan propos plai role progesteron-depend cell growth inhibit materi method human cell line c-4i deriv squamou carcinoma uterin cervix progesteron receptor-neg cultur medium contain v/v fetal calf serum cell grow monolay expos variou progesteron concentr flow cytometri morphometri emploi assess effect result progesteron caus concentr-depend growth inhibit ic50 valu 2.06 +/- 0.46 microm mean valu +/- sem 320 microm viabl attach cell left two mechan appear respons effect firstli cell accumul g1/g0-phase indic cell cycl-specif arrest secondli progesteron induc cell death apoptosi necrosi morphometr analysi show progesteron caus mark reduct nuclear size compat apoptosi conclus present result show progesteron exert non-genom effect reduc input acceler exit cell c-4i cell popul
alpha-tocopherol synthet deriv a-tocopheryl succin alpha-ts known inhibit prolifer cancer cell alpha-ts consid desir anticanc agent becaus abil induc apoptosi establish previous whole intact alpha-ts molecul necessari pro-apoptot activ reason alpha-ts suitabl oral us becaus ester bond link succin tocopherol subject hydrolysi intestin esteras on approach overcom problem replac ester bond ether bond latter resist esteras-mediat hydrolysi alpha-tocopheryloxybutyr alpha-tob ether analog alpha-ts studi compar potenc alpha-ts alpha-tob us panel bioassai cell growth tunel label apoptosi parp cleavag caspas-3 caspas-9 activ well akt jnk phosphoryl experi carri two human prostat cancer cell line lncap pc-3 result show alpha-tob capabl inhibit cell growth induc apoptosi alpha-tob activ alpha-ts equimolar basi gener took twice much alpha-tob alpha-ts achiev same respons nonetheless two compound share same mechan target akt jnk signal pathwai activ intrins cell death mediat caspas-9 caspas-3 cellular analysi alpha-ts alpha-tob show alpha-tob taken effici alpha-ts suggest lower activ alpha-tob inher properti molecul due impair uptak addit evid provid show beta-ts act membran level interfer akt phosphoryl exact natur disrupt remain unclear futur design anticanc tocopherol analog incorpor ether linkag side chain esteras resist well structur modif enhanc block membran signal
previou studi reveal lactoferrin reconstitut cellular humor immun respons cyclophosphamid-treat mice aim investig establish whether suppressori effect methotrex mtx cellular humor immun respons modul found mtx given intraperiton i.p dose 200 mg/kg b.w sensit cba mice ovalbumin ova reduc delai type hypersensit dth respons co-administr drink water 0.5 solut durat experi dai restor dth respons almost control level howev abl restor primari humor immun respons measur number antibodi-form cell afc sheep erythrocyt srbc spleen mtx mg/kg b.w administ mice i.p 48h post immun hand mice treat second challeng srbc show signific restor mtx-suppress humor immun respons booster immun addit microg/ml restor secondari humor immun respons srbc vitro mtx 0.05-1 ad cell cultur dai cell cultur initi data demonstr preferenti restor cellular immun respons impair mtx treatment seem prevent block activ memori cell secondari humor immun respons taken togeth demonstr given oral reduc toxic effect mtx
background cellular oxid stress major caus dna damag still clear degre affect genet instabl malign progress establish prostat carcinoma pca materi method examin express cdkn1a gadd45 protein act cell cycl checkpoint dna repair pca rel presenc oxid dna damag measur detect dna adduct 8-hydroxi-2-deoxyguanosin 8-ohdg sixteen pca benign prostat hyperplasia bph analyz rt-pcr us evalu waf1 gadd45 transcript western blot elisa us analyz protein 8-ohdg adduct prolifer studi ki67 imag cytometri telomeras activ detect trap- elisa result multivari factor analysi provid evid pca dna checkpoint protein associ 8-ohdg prevent neoplast cell prolifer convers bph oxid dna damag invers correl dna checkpoint protein prolifer suggest presenc energi-deplet senesc cell conclus non-malign tissu extens oxid dna damag drive cell metabol blockag pca neoplast cell activ repair mechan favor escap senesc expans dna-damag clone
background anti-angiogenesi strategi wide recogn viabl approach fight cancer anti-angiogen factor continu identifi among muscular isoform troponin tni describ power anti-angiogen agent vitro well vivo investig therapeut efficaci tni gene therapi human-like orthotop rat osteosarcoma model materi method tumor model evalu whether administr secret tni code sequenc complex cation liposom name tnitag cdna/lclp induc delai tumor growth reduc tumor vasculatur result tni specif inhibit endotheli cell growth vitro abl demonstr therapeut efficaci tni transplant osteosarcoma model conclus lack efficaci probabl result rapid degrad recombin tni matrix metalloproteinas especi mmp2 present larg amount tumor
background descript method measur complex prostat-specif antigen cpsa offer approach diagnosi prostat cancer patient method measur psa hybritech bayer free psa hybritech complex psa bayer patient prostat cancer 128 benign prostat hyperplasia result conclus found increas sensit us ng/ml cut-off cpsa relat total psa us cut-off ng/ml 35.5 similar differ found specif cpsa total psa defin grai zone patient cpsa 2.5 ng/ml measur free/complex psa ratio save import number neg biopsi maintain higher sensit
differenti diagnost borderlin ovarian tumour ovarian carcinoma gener base morpholog criteria suffici final diagnosi investig practic diagnost applic ca200 imag analyz ploidi-relat paramet seri borderlin tumour low-grade carcinoma ovari highli signific differ borderlin malign lesion found percentag diploid cell 0.0001 percentag aneuploid cell 0.0001 percentag octaploid cell 0.0001 well exceed rate 0.0001 differ concern ratio tetraploid cell reach level signific 0.0320 suggest ploidi-relat paramet evalu ca200 imag analyz help ovarian lesion unclear morpholog
human papillomaviru hpv seem involv head neck carcinogenesi investig associ viral presenc express analys polymeras chain reaction pcr -base method correl tumour local clinic-patholog aspect alcohol tobacco exposur patient hpv dna found case 24.6 hpv type detect hpv16 case hpv case hpv on case tonsil locat highest hpv posit 6/8 percentag significantli higher found tumour site p&lt 0.01 viral transcript earli region detect hpv16 posit tumour hpv statu relat ag gender tumour stage grade us alcohol tobacco result suggest hpv16 activ involv genesi subset head neck cancer tonsillar local consid hot spot viral transform
studi enzym glutaminas purifi ascit fluid ovarian cancer patient analys antiangiogen activ intraperiton administr enzym reduc number tumor direct capillari solid ascit tumor bear swiss mice induc transplant ehrlich ascit cell enzym critic role regul secret vascular endotheli growth factor vegf tumor cell turn tumor growth glutamin analogu like 6-diazo oxo l-norleucin don found effect regul vascular endotheli growth factor vegf secret tumor cell vitro treatment enzym reduc serum vegf level tumor induc anim vitro vegf product eac cell reduc concentr depend manner presenc glutamin analogu
popul-base registri patient histolog verifi testicular lymphoma identifi diffus larg b-cell lymphoma dlbcl peripher t-cell lymphoma two case twenti-two patient local diseas stage twenti-eight patient receiv system chemotherapi receiv intrathec prophylaxi receiv radiotherapi contralater testi stage i/ii group patient complet remiss relaps cn involv isol cn relaps three remark late relaps occur 127 month intrathec prophylaxi seem reduc frequenc relaps involv cn rel short follow-up median month rang 34-88 censor patient prevent firm conclus regard efficaci outcom stage patient poor patient continu immunohistochem analysi dlbcl tumour reveal germin centr b-cell-like phenotyp cd44 express tumour stage patient half stage i/ii patient high intratumour microvessel densiti correl high degre ki-67 posit tumour cell inferior overal surviv
heat shock protein hsp70 plai essenti cellular role mediat intracellular protein fold protect cell proteotox stress studi examin role hsp70 express apoptosi prostat carcinoma cell apoptosi neg correl hsp70 express pc-3 cell heat shock vivo experi carri vitro reconstitut system isol nuclei cytoplasm pc-3 cell show purifi hsp70 directli inhibit apoptosi dose-depend manner potenti role deplet intracellular hsp70 examin mean induc apoptosi pc-3 cancer cell deplet hsp70 two independ strategi anti-sens oligonucleotid direct hsp70 mrna bioflavinoid drug quercetin led apoptosi absenc stress addit quercetin pre-treatment synergist enhanc apoptosi combin heat shock hsp70 plai physiolog role tumour cell inhibitor apoptosi occur both spontan stress potenti target apoptosi-base cancer therapi
proteasom inhibitor bortezomib shown activ chemotherapi-resist tumor approv treatment multipl myeloma critic compon bortezomib's antitumor activ inhibit nuclear factor-kappa nf-kappab patient ovarian cancer respond initi platinum-base chemotherapi cisplatin howev agent shown induc tumor cell surviv induc nf-kappab activ phase trial bortezomib solid tumor includ ovarian cancer summar examin determin compound overcom impact chemoresist on trial singl-agent bortezomib advanc malign deem safe manag drug potenti efficaci solid tumor second phase trial explor inhibit nf-kappab bortezomib drug render platinum agent sensit ovarian cancer patient seven nine patient studi major respons combin carboplatin bortezomib two trial indic promis result bortezomib patient solid tumor patient recurr ovarian cancer investig warrant
studi evalu associ ovarian cancer alcohol intak inconsist few evalu associ context folat consumpt dietari folat alcohol intak lifestyl medic inform collect self-administ questionnair 1986 postmenopaus women ag 55-69 follow prospect year risk epitheli ovarian cancer iowa women's health studi among 205 elig women free baselin cancer 147 incid epitheli ovarian cancer case identifi linkag cancer registri compar lowest quartil total folat food plu supplement intak multivari risk ratio increas quartil 1.0 refer 1.59 1.24 1.73 confid interv [ci] 0.90-3.33 trend 0.20 compar non-drinker rr increas alcohol intak 1.0 refer 0.78 0.01-3.9 g/d 0.75 4.0-9.9 g/d 0.58 g/d 0.30-1.11 trend 0.08 among women alcohol intak g/d compar &lt g/d appar risk reduct limit total folat intak 331 microg/d 0.52 0.22-1.19 interact 0.04 estim base seven case associ chang appreci exclud tumor mucin histolog find suggest alcohol consumpt invers relat postmenopaus ovarian cancer associ folat ovarian cancer vari amount alcohol consum
tumor format immunocompet host believ depend abil tumor cell evad immun system suggest alter express major histocompat complex mhc relat molecul number cancer previou serial analysi gene express sage studi reveal hla-dra encod alpha chain hla-dr on most highli overexpress gene ovarian cancer find unanticip overexpress mhc molecul expect increas tumor immunogen compromis tumor growth examin express hla-dr alpha chain ovarian varieti cancer us tissu arrai found overexpress major cancer tissu investig contrast hla-dr beta chain togeth alpha chain form function hla-dr complex frequent found express cancer result lack matur hla-dr tissu interestingli hladra hladrb transcript both found express cancer type includ ovarian cancer suggest downregul hladr beta chain post-transcript post-translat mechan addit observ high level invari chain ii/cd74 express both cytoplasm plasma membran ovarian tumor cell possibl contribut lack matur hla-dr protein express interestingli found ifn-gamma induc matur hla-dr surfac normal ovarian cell abil reduc tumor cell togeth data suggest ovarian tumor overexpress hla-dr alpha result inflammatori event tumor microenviron tumor cell compensatori mechan reduc product function mhc class molecul reduc immunogen favor tumor growth addit becaus ubiquit express ovarian cancer hla-dr alpha repres novel biomark malign
human mismatch repair mmr gene encod highli conserv interact protein correct replic error predispos hereditari gastrointestin genitourinari malign subset sporad genitourinari tumor exhibit mmr defici identifi measur frequenc microsatellit instabl msi cancer cell dna investig express two most commonli mutat mmr gene msh2 mlh1 sporad testicular germ cell tumor gct order determin express pattern msh2 mlh1 protein normal seminifer tubul histolog distinct gct subtyp correl mmr gene express genet instabl gct develop panel molecular marker identifi genet distinct subset gct prognost assess msh2 mlh1 differenti stain pattern normal seminifer tubul malign tissu msh2 express stage spermatogenesi exclud matur sperm wherea mlh1 predominantli express premeiot germ cell histolog gct subtyp show differenti immunostain msh2 mlh1 howev pure seminoma statist signific fewer low msh2 stain tumor subtyp 0.046 twenti-five percent gct exhibit increas frequenc msi msi+ tumor msi+ tumor exhibit low msh2 low mlh1 low msh2 low mlh1 stain respect fifteen percent testicular gct exhibit loss heterozygos loh msi loh tumor loh tumor exhibit low msh2 low mlh1 low msh2 low mlh1 stain respect
inaugur confer tucson arizona 6-9 2004 brought togeth clinic basic scientist discuss recent research advanc understand target progress human prostat cancer inform meet uniqu provid opportun discuss interact differ group scientist path rare cross goal meet develop novel approach understand human prostat cancer order uncov therapeut target faculti six differ cancer center repres includ memori sloan-ketter cancer center york arizona cancer center tucson fred hutchinson cancer center seattl chao famili comprehens cancer center irvin sydnei kimmel cancer center san diego jonsson comprehens cancer center univers california lo angel univers massachusett memori cancer center worcest sever import concept emerg meet result basic clinic scienc interfac concept includ human prostat cancer uniqu biolog featur compar human epitheli malign tumor plastic evid earli prostat cancer progress evidenc alter extracellular matrix therapeut strategi includ co-target stroma prostat cancer cell-cell cell-ecm adhes switch revers phenotyp evid earli human prostat tumor progress discoveri molecular signatur includ genom proteom pattern discrimin indol versu aggress diseas potenti power tool requir multifactori approach success biomark innov tissu specif imag modal human prostat cancer develop aid accur assess prostat cancer patient
aim chemokin chemotact cytokin known import direct migrat chemotaxi leucocyt condit homeostasi inflammatori immunolog respons howev role chemokin extend beyond involv mediat leucocyt traffick increas bodi evid suggest protein intim involv stage tumour develop progress aim studi role cxcl12 cxcr4 chemokin ligand receptor complex determin organ-specif metastasi prostat cancer materi method cxcr4 mrna express determin rt-pcr metastat prostat cancer cell line du145 lncap pc3 primari prostat cancer cell line 1542 cpt3x normal prostat epitheli cell line 1542 nptx pre 2.8 follow taqman quantit pcr analysi cxcr4 mrna cell line flow cytometri analysi us measur express cxcr4 receptor protein cell surfac influenc receptor cell migrat studi us transwel migrat assai final taqman quantit pcr perform rna obtain laser microdissect fresh primari prostat tumour benign tissu sampl patient result du145 lncap pc3 cxcr4 mrna express approxim 1000 400 time respect 1542 nptx pre 2.8 1542 cpt3x patient primari tumour sampl patient benign tissu specimen cxcr4 mrna express similar metastat cell line du145 flow cytometri analysi show significantli higher level cxcr4 receptor present cell surfac metastat cell line migrat studi reveal chemotaxi metastat cell line pc3 du145 enhanc cxcl12 ligand inhibit antibodi cxcr4 cxcl12 influenc migrat normal prostat epitheli cell line 1542 nptx conclus demonstr human prostat cell line deriv metastas express function cxcr4 receptor cxcl12 ligand enhanc migratori capabl laser microdissect primari patient tumour patient benign tissu specimen express cxcr4 mrna high level suggest post-transcript modif cxcr4 receptor plai major role regul protein express result suggest prostat cancer influenc cxcl12 cxcr4 pathwai metastasi pathwai provid novel target therapeut intervent
imatinib mesyl novel anti-tumor agent us clinic manag chronic myelogen leukemia gastrointestin stromal tumor minim toxic rel form cancer therapi clinic activ minim toxic relat specif inhibit cellular target includ bcr-abl platelet-deriv growth factor receptor c-kit kinas result collaps downstream signal cascad import transform patient unexpect toxic aris associ inhibit known cellular imatinib target report investig effect imatinib squamou carcinoma cell signal imatinib induc express cox-2 dose-depend manner concomit accumul prostaglandin cox-2 induct imatinib initi through epiderm growth factor egf receptor kinas activ downstream signal through mitogen-activ protein kinas cox-2 induct imatinib block mek1 egf receptor inhibit imatinib activ stressor cytokin-signal pathwai p38 kinas nuclear factor-kb nuclear transloc affect cox-1 express imatinib fail activ egf receptor signal tumor type suggest cox-2 induct imatinib-treat cell mediat through releas autocrin factor express activ squamou tumor cox-2 induct imatinib squamou tumor deriv head neck region uniqu respect target-specif agent repres on unintend toxic effect imatinib describ patient
previou studi suggest antagonist cyclooxygenas cox-1 inhibit angiogenesi tumor xenograft molecular mechan involv remain unclear here character effect non-select indomethacin select ns398 celecoxib cyclooxygenas inhibitor paramet angiogenesi human pancreat adenocarcinoma cell cox-1 express constitut 9/9 pancreat cancer cell line wherea cox-2 cytosol phospholipas cpla2 express observ 4/9 cell line bxpc3 capan2 cfpac1 l3.6 product cox product prostaglandin correl express cpla2 cox-2 block non-steroid anti-inflammatori drug nsaid indomethacin ns398 contrast find other neither indomethacin nor ns398 affect tumor cell secret angiogen factor vegf bfgf il-8 concentr produc maxim inhibit pge2 product higher concentr increas angiogen factor product studi effect celecoxib orthotop l3.6 xenograft immunofluoresc analys reveal high-level express cox-2 endotheli cell l3.6 xenograft increas therapi celecoxib wherea tumor cell express uniformli low level cox-2 celecoxib decreas tumor-associ vegf level orthotop human l3.6 xenograft drug decreas tumor microvessel densiti mvd increas apoptosi tumor-associ endotheli cell dose-depend fashion togeth result demonstr anti-angiogen effect nsaid human pancreat cancer cell exert via direct effect endotheli cell
introduct malign cell capabl unlimit number cell divis through product telomeras through altern lengthen telomer alt mechan yeast cell genom instabl shown surviv absenc telomeras increas recombin event hypothes ovarian cancer high microsatellit instabl msi-h like lack telomeras activ method examin 104 invas ovarian cancer msi six microsatellit marker bat25 bat26 d5s346 d2s123 d17s250 nme1 telomeras activ determin elisa subunit human telomeras revers transcriptas htert human telomeras rna htr rt-pcr statist analysi perform chi-squar p&lt 0.05 consid signific result telomeras activ detect sampl htert subunit detect sampl htr found ovarian cancer presenc htert posit associ telomeras activ 0.001 high msi msi-h defin two posit marker detect ovarian cancer low msi msi-l defin have on posit marker found remain microsatellit stabl msi-s telomeras activ detect msi-s msi-l tumor msi-h tumor 0.002 interestingli htert similar three group rang 73-84 0.59 demonstr presenc htert transcript determin telomeras activ msi-h tumor conclus ovarian cancer high msi like propag need produc telomeras
antivascular therapi provid promis method anticanc therapi target gastric cancer vessel nonselect due part lack specif cell-surfac receptor identifi target vascular cell herein us vivo screen phage displai peptid librari identifi peptid bind select endotheli cell human gastric cancer rather nonendotheli cell four round select on phage obtain cyclic 7-mer peptid cgnsnpksc home human gastric adenocarcinoma .there 4.6 approxim 137.26-fold increas number select phage gastric cancer xenograft comparis control organ brain heart liver spleen kidnei immunohistochemistri mous human tissu show phage peptid bind endotheli cell human gastric cancer peptid observ specif bind huvec sgc-7901 eca-109 lovo hep-g2 elisa competit inhibitori result synthet cgnsnpksc peptid phage displai peptid cgnsnpksc huvec vivo confirm specif bind effect peptid possibl candid target drug deliveri antivascular therapi
endostatin endogen inhibitor angiogenesi deriv extracellular matrix protein collagen xviii report variat 104 posit d104n human endostatin associ increas risk prostat cancer potenti indic protein variant activ anti-angiogen agent herein report result genotyp 389 patient androgen independ prostat cancer aipc 352 normal control individu d104n endostatin signific associ frequenc 104n endostatin incid aipc caucasian african american patient compar control caucasian aipc versu 13.7 caucasian control 0.79 7.4 african american aipc versu 5.6 african american control 0.64 actuari analysi reveal statist signific associ incid heterozyg genotyp surviv 0.62 logrank test studi function signific d104n convers express purifi insolubl recombin human 104d 104n endostatin compar respect activ human umbil vein endotheli cell huvec tube format assai 104n variant human endostatin inhibit huvec tube format least well wild-type form conclud d104n variat human endostatin neither clinic relev nor suitabl pharmacogenom endpoint assess risk develop aipc
antiangiogen metronom chemotherapi frequent administr convent cytotox agent low dose believ target activ tumor endotheli cell mechan action regimen remain poorli understood march 2004 issu cancer research hamano demonstr low-dose cyclophosphamid inhibit tumor growth upregul endogen angiogenesi inhibitor thrombospondin-1 tumor perivascular cell thrombospondin-1 turn promot endotheli cell apoptosi propos thrombospondin-1 level us surrog marker monitor respons low-dose cyclophosphamid therapi clinic
phosphatidylinositol 3-kinas pi3-kinas novel intracellular transduc involv wide rang cancer-associ signal pathwai compris variou isoform splice variant distinct biolog activ clinic implic especi class pi3-kinas 110 catalyt subunit alpha pik3ca most import isoform tumorigenesi possibl tumor angiogenesi sever strategi develop block pi3-kinas cancer therapi howev approach target specif pi3-kinas isoform explor date present studi show rna interfer rnai through small interf sirna sequenc target pik3ca potenti applic isoform-specif knock-down pi3-kinas strategi provid novel tool studi function variou pi3-kinas isoform contribut isoform-specif target pi3-kinas human cancer
membran glycoprotein cox2 regul transcript post-transcript level pro-inflammatori agent cytokin growth factor oncogen tumor-promot cox2 express earli stage colorect carcinogenesi premalign adenoma stage adenocarcinoma stomach colon breast lung prostat express detect neoplast inflammatori endotheli stromal cell cox2 involv convers arachidon acid prostaglandin thromboxan well synthesi malonaldehyd mda mutagen product hydrogen peroxid promot carcinogenesi cox2 product act turn serpentin receptor coupl heterotrimer g-protein r-txa2 r-pg connect signal element implic oncogenesi cox2 plai kei role earli stage carcinogenesi promot prolifer tumor cell resist apoptosi well angiogenesi tumor cell invas set metastat process mechan establish rational behind therapeut target cox2 human solid tumor
chemoprevent us natur synthet compound order revers suppress prevent carcinogen process among pathwai dysregul carcinogen process cyclooxygenas-2 cox2 seem on most promis pathwai target order achiev chemoprevent anticanc effect inde cox2 overexpress contribut carcinogen least differ mechan includ transform procarcinogen carcinogen pro-inflammatori immunomodulatori effect resist apoptosi angiogenesi invas progress.. review will focu rational ongo research area relat chemoprevent approach target cox2
cyclooxygenas-2 cox2 induct isoenzym cyclooxygenas undetect normal colon mucosa overexpress colon tumor sever work vitro vivo show cox2 plai kei role multistep process colorect tumorigenesi apoptosi inhibit cellular prolifer angiogenesi induct cox2 repres potenti molecular target colorect manag specif cox2 inhibitor us chemoprevent well therapeut agent human anim studi cox2 inhibitor shown effect human cox2 inhibitor approv food drug administr adjunct endoscop surveil surgeri patient famili adenomat polyposi fap purpos articl review relationship cox2\cox2 inhibitor differ signal pathwai colorect carcinogenesi precis possibl molecular mechan action work review clinic data efficaci chemoprevent agent well therapeut differ group risk colorect cancer
pge2 on most import prostaglandin involv oncogenesi pge2 found high concentr level most epitheli cancer urolog gynaecolog cancer express enzym origin pge2 cyclooxygenas cox2 inhibitor present anticanc properti demonstr wide varieti cellular anim model human applic current test clinic trial bladder prostat uterin carcinoma
seriou digest side effect select inhibitor induc cyclooxygenas-2 reduc compar nonselect non-steroid anti-inflammatori drug main risk factor associ gastro-intestin ulcer caus latter found select inhibitor taken long period ag year anteced gastro-duoden ulcer concomit aspirin treatment contrast pylori infect found risk factor apart past histori gastro-duoden ulcer complic lower digest tract twice frequent select inhibitor nonselect anti-inflammatori drug nevertheless seem risk exacerb inflammatori coliti reduc cardiovascular complic discuss rofecoxib taken supra-therapeut dosag recognis increas incid myocardi infarct increas found usual dosag celecoxib select inhibitor reduc renal sodium excret increas blood pressur particularli hypertens patient blood pressur regularli check
rational introduc ion beam cancer therapi high level physic select achiev ion equal better proton beam modern photon techniqu well potenti advantag high-let radiat tumour type site radiobiolog argument high-let radiat cancer therapi review reduct oer case hypox poorli-reoxygen tumour lesser import repair phenomena problem control repair-profici photon-resist tumour fast neutron first type high-let radiat us clinic appli under suboptim technic condit nevertheless us clinic inform deriv neutron experi greater benefit neutron convent radiotherapi found sever tumour site present discuss limit result salivari gland tumour prostat adenocarcinoma base fast neutron experi radiobiolog argument ad benefit excel physic select ion beam potenti clinic indic high-let ion discuss hypox slowli grow well-differenti photon-resist tumour on main remain issu select individu patient high- low-let radiat physic select ion match obtain techniqu select patient will base radiobiolog characterist tumour
aim studi evalu anti-angiogen activ combin intermedi dose thalidomid dexamethason patient refractori/relaps myeloma twenti-five patient includ studi microvessel densiti mvd evalu marrow biopsi befor treatment serum level vascular endotheli growth factor vegf basic fibroblast growth factor b-fgf tumor necrosi factor-alpha tnf-alpha angiogen potenti interleukin-6 il-6 il-1beta solubl il-6 receptor sil-6r transform growth factor-beta tgf-beta involv diseas biologi measur befor treatment everi week week pretreat level mvd vegf b-fgf il-6 sil-6r increas patient compar control overal respons rate therapi administr combin regimen produc signific reduct mvd respond howev increas serum level vegf b-fgf il-6 sil-6r observ post-treatment respond contrast serum level tnf-alpha tgf-beta il-1beta differ patient control remain unchang studi result suggest combin thalidomid plu dexamethason effect treatment myeloma reduc mvd marrow level serum level angiogen cytokin cytokin implic myeloma biologi
pten phosphatas tensin homologu delet chromosom p53 alter expect divers involv endometri carcinogenesi patient endometri carcinoma analyz pten p53 immunostain tissu section tumor histolog grade differenti presenc endometri hyperplasia stain statu pten p53 clinic inform examin case neg pten stain suggest lost reduc pten function loss pten stain significantli relat advanc stage grade grade endometrioid adenocarcinoma group 0.026 case show posit stain p53 p53 stain larg found grade endometrioid adenocarcinoma phenotyp group case reduc pten stain show p53-neg stain 0.025 other group case reduc pten stain show p53-posit stain p53-posit stain associ high probabl tumor recurr group 0.0234 contrast other group p53-posit case low probabl tumor recurr 0.0473 both pten p53 stain good indic clinic stage probabl tumor recurr reciproc abnorm p53 pten occur earli phase carcinogenesi howev simultan abnorm p53 pten occur late phase carcinogenesi immunohistochemistri pten p53 biopsi specimen provid support inform determin treatment plan
identif gene express cancer cell-specif manner provid marker detect diagnosi diseas progress previous report receptor tyrosin kinas ligand concert ligat alphavbeta5 integrin induc express mig-7 restrict carcinoma cell becaus highli specif express hypothes mig-7 us marker occult tumor cell object studi test hypothesi gener mig-7 specif antisera rt-pcr method detect mig-7 express tissu blood cancer patient compar normal subject immunohistochemistri rt-pcr detect mig-7 mrna lymph node 77.8 endometri carcinoma xenograft mice neg control anim mig-7 express specif met express rtk bind scatter factor us marker poor progress endometri carcinoma compar normal endometri tissu sampl 87.3 tumor variou tissu includ breast lung colon ovari detect mig-7 express blood sampl untreat metastat cancer patient displai mig-7 mrna contrast lack express chemotherapi treat normal individu conclus report first immunohistochem rt-pcr assai mig-7 discuss highli specif local cancer cell contrast absenc normal cell preliminari data indic mig-7 potenti earli marker migrat circul carcinoma cell
goal studi examin effect ursol acid pentacycl triterpenoid compound growth endometri cancer cell line sng-ii found ursol acid strongli inhibit growth sng-ii cell dose- time-depend manner morpholg chang characterist apoptosi observ treat cell presenc apoptot bodi fragment dna oligonucleosom-size fragment investig activ form caspas-3 ursol acid-treat sng-ii cell microm strength ursol acid induc mark increas caspas-3 activ approxim 5-fold control cell level cleav caspas-3 increas time- dose-depend manner activ caspas led cleavag target protein parp ursol acid treatment result cleavag poli adp-ribos polymeras dose-depend manner test whether caspas-3 activ dna polymeras activ inhibit addit ac-dedv-hco ursol acid treatment show microm ac-dedv-hco inhibit caspas-3 activ treat cell dna fragment observ ursol acid treatment dna fragment occur sng cell treat both ac-dedv-hco ursol acid becaus research suggest mitochondri pathwai involv ursol acid-induc apoptosi secondari induct mitochondri cytochrom releas studi mitochondri event ursol acid-induc apoptosi cell line ursol acid treatment anti-apoptot bcl-2 protein decreas bax express enhanc result indic ursol acid induc apoptot process endometri cancer sng-ii cell line through mechan involv mitochondri pathwai bcl-2 famili protein
background object cowden syndrom rare autosom domin disord character multipl hamartoma increas risk breast thyroid cancer possibl endometri carcinoma suscept cowden syndrom confer germlin mutat pten tumor suppressor gene somat mutat pten common sporad endometri carcinoma aim studi test whether substanti proport endometri cancer associ germlin mutat pten gene necessarili associ clinic overt cowden syndrom method retrospect cohort 240 consecut patient patholog confirm endometri carcinoma diagnos institut 1999 2002 ascertain studi genom dna isol peripher blood lymphocyt entir pten code region exon-intron junction screen mutat singl strand conform polymorph analysi potenti variant subject direct sequenc analysi result clearli deleteri pten sequenc variant identifi screen cohort endometri cancer patient on patient harbor 5-bp delet intron region adjac splice acceptor site pten exon variant previous classifi rare polymorph conclus data preclud possibl increas risk endometri cancer associ cowden syndrom indic germlin pten mutat account signific proport genet attribut risk endometri carcinoma
object studi undertaken character subcellular local two major isoform progesteron receptor pra prb endometri cancer method immunohistochemistri immunoprecipit confoc microscopi perform us hec50co kle endometri cancer cell model express pra prb consequ transduct locat prb compar pra determin antibodi test specif respect isoform recognit immunohistochem analys express subcellular compartment perform formalin-fix endometri cancer tumor result morpholog biochem evalu demonstr pra local nucleu absenc progesteron contrast larg proport prb cytoplasm absenc ligand rapidli transloc nucleu presenc progesteron differenti distribut pra prb prove hallmark malign nonmalign epithelia sampl archiv endometri tissu women pre-oper diagnosi endometri cancer endometri cancer specimen demonstr cytoplasm prb cell five seven tumor moder poorli differenti demonstr prb stain nuclei nuclear prb significantli associ increas tumor differenti 0.031 conclus absenc ligand pra nuclear prb larg cytoplasm suggest pra exert ligand-independ nuclear effect prb nongenom cytoplasm action endometri cancer cell
introduct placent site trophoblast tumor pstt rare variant gestat trophoblast diseas re-describ 1970s materi method patient' ag present present symptom descript pregnanc treatment outcom analyz five patient diagnos pstt depart 1973 2003 result describ clinic outcom patient pstt four diagnos treat 2001 mean interv pregnanc diagnosi 5.1 month rang 0-10 month vagin bleed present symptom five patient instead standard hysterectomi follow chemotherapi indic on patient underw fertil preserv manag us hysteroscop resect tumor follow chemotherapi conclus combin oper hysteroscopi chemotherapi women local diseas want preserv fertil possibl treatment option highli select patient repeat chemotherapi ema/ep patient relaps treatment ema/ep pstt induc prolong remiss cure
object loss cell cycl control critic step develop neoplasia p16 protein identifi tumor suppressor protein bind specif cyclin-depend kinas cdk-4 inhibit catalyt activ cdk4-cyclin complex therebi act neg cell cycl regul present studi compar express p16 protein case leiomyoma uterin smooth muscl tumor uncertain malign potenti stump leiomyosarcoma lm method p16 express investig immunohistochemistri paraffin-embed tissu patient leiomyoma patient stump patient lm result p16 express leiomyoma stump lm statist signific differ regard frequenc p16 protein express observ lm stump &lt 0.05 well lm leiomyoma &lt 0.05 stump leiomyoma 0.05 likewis stain intens significantli differ lm leiomyoma lm stump &lt 0.05 statist signific differ observ stump leiomyoma 0.05 statist signific correl p16 express clinic stage ag vascular space involv recurr diseas found patient lm 0.05 addition overal surviv significantli differ p16-posit p16-neg case 0.05 conclus found p16 frequent strongli express lm compar stump leiomyoma conclud p16 plai import role sarcomagenesi furthermor p16 us immunohistochem marker help distinguish case smooth muscl tumor histolog featur ambigu borderlin us p16 diagnost set await clinic studi clarif mechan
object determin toxic toler feasibl deliv combin chemotherapi subsequ radiat therapi women high-risk endometri cancer evalu long-term bowel toxic regimen method trial approv dana farber/partner cancer care dfpcc institut review board irb patient stage stage endometri cancer patient high-risk histolog stage diseas prospect enter complet surgic stage normal gate blood pool scan requir prior entri patient treat three cycl paclitaxel 160 mg/m doxorubicin mg/m carboplatin auc tac dai 21-dai schedul outpati g-csf support conclus chemotherapi patient receiv radiat therapi 4500 cgy whole pelvi commenc dai cycl chemotherapi paraaort radiat vagin brachytherapi allow discret treat radiat oncologist result twenti patient enter onto trial novemb 2000 through februari 2003 eighteen patient successfulli complet trial two patient came trial chemotherapi both later complet plan radiat therapi patient initi stage stage stage papillari serou domin histolog patient chemotherapi given averag dai surgeri rang 11-63 dai radiat initi averag week surgeri rang 10-18 week chemotherapi well toler total cycl deliv plan cycl two patient requir dose modif two cycl two patient cycl secondari hematolog toxic grade grade neurotox report six episod grade short-term toxic radiat therapi report singl patient late radiotherapi toxic includ bowel obstruct requir laparotomi two patient grade constip on patient late radiat toxic data still collect follow-up continu conclus tac chemotherapi regimen well toler three cycl deliv successfulli g-csf support evid neurotox cardiac toxic report cisplatin contain tap regimen standard radiat deliver tac therapi excess toxic studi regimen subsequ radiat therapi warrant patient risk system region recurr malign
object us tyrosin kinas inhibitor tki result success treatment kit-posit neoplasm carcinosarcoma aggress neoplasm consequ c-kit express signific clinic implic tumor purpos present studi assess c-kit express carcinomat sarcomat element carcinosarcoma identifi kit repres therapeut target treatment neoplasm method immunohistochem stain c-kit perform paraffin-embed tissu block consecut uterin specimen carcinosarcoma endometri carcinoma atroph endometrium two pathologist assess score index stain result stromal element carcinosarcoma immunohistochem c-kit stain cell observ epitheli element low score index stain present endometri endometrioid carcinoma score index high specimen atroph endometrium low score index specimen conclus result seem suggest c-kit probabl plai major role pathogenesi major tumor involv pathogenesi endometri carcinoma view multipl molecular target activ imatinib mesyl definit conclus drawn regard effect carcinosarcoma base present studi studi c-kit express larger seri carcinosarcoma order settl controversi issu regard frequenc express prognost clinic valu warrant
object binari grade system propos assess amount solid growth pattern invas presenc necrosi therebi divid endometri endometrioid carcinoma low- high-grade tumor analyz system predict prognosi respect inter- intraobserv reproduc treatment modal method total 200 endometri carcinoma base hysterectomi specimen grade accord binari grade system comparison intern feder gynecolog obstetr figo system nuclear grade result both inter- intraobserv agreement us binari grade system kappa 0.57 percent agreement kappa 0.62 superior compar figo system 0.50 0.62 nuclear grade 0.23 0.43 patient earli-stage low-grade tumor rate 5-year surviv 5ys patient earli-stage high-grade tumor advanc-stage low-grade tumor respect rate 5ys patient advanc-stage high-grade tumor rate 5ys binari low-grade earli-stage tumor patient outcom better adjuv therapi chemotherapi compar therapi conclus binari grade system superior other permit greater reproduc predict prognosi endometri cancer patient
purpos despit similar chemotherapeut manag advanc gestat trophoblast diseas gtd ovarian germ cell tumor import differ exist malign particularli us cisplatin method three patient persist recurr gtd care cleveland clinic receiv high-dose chemotherapi program stem cell support on manag etoposid-associ acut leukemia result standard dose treatment program result indic us dose-intens strategi ultim clinic cours differ three patient collect case rais relev question regard optim manag high risk recurr gtd conclus experi repres report support earlier us cisplatin-base chemotherapi manag high-risk recurr gtd possibl administr high-dose chemotherapi program rare patient recur standard dose platinum-base treatment
object studi relationship chang gene express profil hydatidiform mole choriocarcinoma hyperplasia trophoblast method differenti express gene analyz two pair tissu hydatidiform mole versu normal villi two pair normal primari cultur trophoblast versu jar cell line chariocarcinoma us cdna microarrai contain 4096 gene confirm result cdna microarrai analysi express up-regul gene relat dna synthesi normal villi hydatidiform mole choriocarcinoma cell line jar jeg-3 examin immunohistochemistri immunoblot rt-pcr result total gene differenti express hydatidiform mole account 2.2 gene arrai gene up-regul down-regul compar normal primari trophoblast 433 gene up-regul 380 gene down-regul jar cell line forti six gene up-regul both hydatidiform mole choriocarcinoma gene down-regul gene associ cell prolif inhibit significantli down-regul wherea associ cell prolifer malign transform metastasi drug resist highli up-regul express thymidin kinas small subunit ribonucleotid reductas rrm2 significantli increas hydatidiform mole jar jeg-3 cell conclus abnorm express gene exist hydatidiform mole choriocarcinoma hyperplasia trophoblast relat over-express gene code synthet enzym
background e-cadherin/beta-catenin complex plai crucial role epitheli cell-cell adhes mainten tissu architectur previous report aberr express beta-catenin endometri carcinoma howev express correl e-cadherin beta-catenin normal malign endometri tissu fulli understood materi method immunohistochem express e-cadherin beta-catenin detect case normal endometrium case endometri carcinoma result normal endometrium express e-cadherin cytoplasm beta-catenin glandular cell predominantli observ prolif phase decreas secretori phase endometri carcinoma express e-cadherin cytoplasm beta-catenin decreas compar normal prolif endometri gland express e-cadherin cytoplasm beta-catenin tend reduc histolog high-grade tumor compar low-grade tumor nuclear express beta-catenin observ glandular cell late prolif earli secretori phase well high-grade endometri carcinoma interestingli nuclear beta-catenin express associ loss e-cadherin express normal carcinoma cell indic invers correl conclus cyclic express e-cadherin beta-catenin normal endometrium suggest adhes complex act maintain endometri architectur addit nuclear beta-catenin express associ loss e-cadherin express involv acquisit aggress biolog behavior especi high-grade tumor
background investig effect 2methoxyestradiol 2-me endogen estrogen metabolit human endometri cancer hec-1-a rl-95-2 cell line materi method exposur hec-1-a rl-95-2 cell 2-me morpholog chang evalu acridin orang stain transmiss electron microscopi cell cycl progress apoptosi necrosi assess flow cytometri dna fragment western blot result 2-me inhibit cell growth block g2/m-phase both cell line induc apoptosi hec-1-a cell caus necrosi rl-95-2 cell apoptosi hec-1-a cell accompani increas express ino stat1 apoptot effect prevent ino inhibitor 1400w elimin caspas inhibitor z-vad-fmk necrosi rl-95-2 cell due sever disrupt mitochondri membran potenti 2-me signific effect normal human endometri cell conclus data suggest 2-me antitumor effect human endometri carcinoma cell hec-1-a rl-95-2 contribut therapeut agent endometri cancer patient
beta3-adrenerg receptor beta3ar stimul lipolysi human fat cell gene constitut candid explain part genet predisposit human obes relat disord trp64arg polymorph beta3ar gene report associ insulin resist obes type diabet littl known possibl associ cancer check associ determin distribut genotyp frequenc allel endometri cancer patient overweight/obes compar appropri control trp64arg polymorph determin pcr-base mspi restrict fragment length polymorph dna peripher blood leukocyt studi popul consist 169 subject among endometri cancer patient control cancer obes bmi kg/m2 overweight bmi bmi kg/m2 individu among endometri cancer patient signific &lt 0.001 differ genotyp distribut allel frequenc endometri cancer patient control cancer odd ratio trp/arg arg/arg genotyp well arg allel consider higher analysi polymorph cancer group patient due bmi reveal distribut genotyp frequenc allel obes/overweight patient differ significantli patient normal weight odd ratio trp/arg genotyp arg allel preval arg allel trp64arg polymorph beta3-adrenerg receptor gene contribut suscept endometri cancer among obes/overweight individu
object studi frequenc insulin resist endometri cancer patient relat clinic cours diseas dna damag evalu possibl approach pharmacolog correct patient studi method sign insulin resist syndrom associ clinic patholog featur diseas dna damag somat cell micronucleu frequenc peripher blood lymphocyt endometri normal tumor tissu alkalin unwind determin endometri cancer patient result frequenc insulin resist syndrom count basi fast plasma glucos insulin concentr accord duncan equal 0.35 0.24-0.46 endometri cancer patient histori diabet mellitu patient well- moder differenti endometri adenocarcinoma mostli type statist significantli higher basal stimul plasma insulin c-peptid concentr patient poorli differenti endometri adenocarcinoma rare encount tumor endometrium primarili type interestingli level fast insulinemia posit correl diseas stage local region tumor dissemin group patient well- moder differenti endometri adenocarcinoma hand hyperinsulinemia hormon-metabol disturb typic insulin resist syndrom increas probabl dna damag somat cell accord data micronucleu test addit associ hormon-metabol disturb degre dna unwind tumor visual unchang endometrium found conclus insulin resist/hyperinsulinemia associ aggress cours diseas certain group patient but--in contrast excess estrogen stimul--doe result increas genotox damag tumor normal tissu data obtain onc confirm need treatment prevent measur aim correct hormon-metabol disturb endometri cancer patient group risk diseas approach includ us antidiabet biguanid thiazolidinedion glitazon statin
latent membran protein lmp on membran-span polypeptid encod epstein-barr viru ebv implic mainten viral latenc appear function part inhibit b-cell receptor bcr signal through itam motif suggest lmp2a involv tumorigenesi mediat ebv studi determin regulatori effect lmp2a telomeras revers transcriptas htert express observ signific constant reduct htert mrna accompani decreas telomeras activ epitheli cell express lmp2a shown lmp2a inhibit htert promot activ transient transfect both cell epitheli cell itam motif requir inhibit lmp2a express lead transcript repress htert gene through specif pathwai therebi contribut control ebv-latenc
clinic signific adenomyomatosi gallbladd remain unclear studi aim clarifi relationship segment adenomyomatosi gallbladd carcinoma elucid histogenesi gallbladd carcinoma associ segment adenomyomatosi total 560 consecut patient underw cholecystectomi specimen examin grossli histolog adenomyomatosi gallbladd divid segment fundal diffus type sixti noncancer gallbladd segment adenomyomatosi examin epitheli metaplasia incid gallbladd carcinoma higher patient segment adenomyomatosi 22/334 6.6 181/4226 4.3 0.049 differ mark among patient equal older year ag 15/96 15.6 versu 147/2407 6.1 respect p&lt 0.001 type adenomyomatosi show signific increas incid gallbladd carcinoma patient both segment adenomyomatosi carcinoma tumor develop fundal mucosa epitheli metaplasia mark fundal mucosa segment adenomyomatosi neck mucosa 0.003 segment adenomyomatosi high-risk condit gallbladd carcinoma especi elderli patient epitheli metaplasia appear relat increas carcinogenesi fundal mucosa segment adenomyomatosi
object investig occup risk factor bladder cancer seven canadian provinc method analys popul-base case-control dataset 887 individu incid histolog confirm bladder cancer 1994 1997 control 2847 frequenc match ag gender survei 1996 questionnair return subject odd ratio or occup self-report exposur adjust provinc ag race smoke sever dietari factor us uncondit logist regress result statist signific increas risk observ among men emploi hairdress 3.42 1.09-10.8 primari metal worker 2.40 1.29-4.50 miner 1.94 1.18-3.17 automechan 1.69 1.02-2.82 primari metal worker automechan show evid employ durat-respons trend modest elev risk signific observ male govern inspector printer firefight gener labour welder durat-respons trend evid govern inspector gener labour femal signific elev observ among lumber processor 8.78 1.28-60.1 gener labour 2.18 1.05-4.52 nurs 1.54 1.03-2.31 gener clerk 1.48 1.01-2.17 latter show posit durat-respons trend conclus studi found statist signific excess risk bladder cancer durat-respons trend among male primari metal worker automechan femal offic worker engag gener cleric duti
object compar urodynam paramet contin rate complic two differ contin urinari reservoir-the sigmoid neobladd w-shape ileal neobladd materi method sixti patient bladder cancer underw radic cystectomi divid two group first group compris patient underw detubular sigmoid neobladd surgeri second group includ patient underw detubuar w-shape ileal neobladd surgeri result earli post-oper complic occur patient sigmoid neobladd group patient ileal neobladd group most complic minor mainli due wound infect urinari leak manag conserv earli post-oper mortal occur patient group dai-time contin achiev 78.8 patient group group respect night-time contin achiev 45.5 patient former group 59.3 patient latter mean neobladd capac 472.5cc patient underw detubular surgeri 463.8cc patient underw detubular surgeri mean post-void residu volum slightli lower group 90.1cc group 93.7cc pelvicalyc system preserv patient group 96.3 patient group signific metabol disturb occur patient group conclus both method good altern bladder substitut surgeon prefer eas construct length mesenteri among factor consid choos
aim studi evalu differ prognost factor affect diseas-specif surviv patient bladder cancer radic cystectomi method juli 1975 decemb 2000 229 patient underw radic cystectomi urinari divers bladder cancer king faisal specialist hospit research center kfsh &amp riyadh saudi arabia 175 patient avail record review retrospect chart review done demograph clinic patholog variabl affect diseas specif surviv bladder cancer patient pool univari multivari analys done diseas specif surviv point result patient 140 male femal mean ag year rang 21-90 year median follow-up period 1.5 year rang on month-19 year five-year diseas specif surviv univari analysi patient' ag lymph node statu patholog stage presenc hydronephrosi signific predictor diseas specif surviv howev lymph node statu p&lt 0.0001 patholog stage 0.0411 &amp presenc hydronephrosi 0.0264 signific predictor diseas specif surviv multivari analysi conclus patholog stage lymph node statu upper obstruct uropathi signific prognost factor bladder cancer patient radic cystectomi factor help defin bladder cancer patient group requir therapi enrol control trial investig addit therapi
